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ABBREVIATIONS 
AAGBI Association of Anaesthetists of Great Britain and Ireland 
ADP  Adenosine diphosphate 
ARDS Acute respiratory distress syndrome 
ASRA American Society of Regional Anesthesia and Pain Medicine 
ATP  Adenosine triphosphate 
AUC  Area under the concentration-time curve 
Bupi  Bupivacaine 
BE  Base excess 
BP  Blood pressure 
cAMP  Cyclic adenosine monophosphate 
CARPA Complement activation related pseudoallergy 
Coca  Cocaine 
Cl  Systemic clearance 
CNS  Central nervous system 
CV  Cardiovascular 
CVP  Central venous pressure 
CYP  Cytochrome P450 
DDD  Daily defined dose 
ECG  Electrocardiogram 
EEG  Electroencephalography 
EF  Ejection fraction 
eNOS  Endothelial nitric oxide synthase 
EtCO2  End-tidal carbon dioxide 
ETS  Electron transfer system 
FCCP  Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 
FiO2  Fraction of inspired oxygen 
G  Glutamate 
GCS  Glasgow Coma Scale score 
i.o.  Intraosseous 
IQR  Interquartile range 
i.v.  Intravenous  
IVRA  Intravenous regional anaesthesia 
Lido  Lidocaine 
LAST  Local anaesthetic systemic toxicity/intoxication 
LBupi  Levobupivacaine 
LCT  Long-chain triglycerides 
logD  Logarithm of octanol:water partition coefficient at physiological pH 
logP  Logarithm of octanol:water partition coefficient at pH 7 
M  Malate 
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MAP   Mean arterial pressure 
MBRT Mean body residence time 
MCT  Medium-chain triglycerides 
Mepi  Mepivacaine 
NADH Nicotinamide adenine dinucleotide 
PaCO2 Arterial carbon dioxide partial pressure 
PaO2  Arterial oxygen pressure 
Prilo  Prilocaine 
PEA  Pulseless electrical activity 
pKa  Dissociation constant 
POPC  1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine 
POPG  1-palmitoyl-2-oleyl-sn-glycero-3-(phospho-rac-[1-glycerol]) 
Ropi  Ropivacaine 
ROSC  Return of spontaneous circulation 
Rot  Rotenone 
RPP  Rate-pressure product 
SD  Standard deviation 
SpO2  Peripheral oxygen saturation 
SR  Sinus rhythm 
Suc  Succinate 
SVRI  Systemic vascular resistance index 
t1/2 Half-time (describing the decrease of drug concentration by 50% though both 
elimination and tissue distribution) 
TAP  Transversus abdominis plane 
TCA  Tricyclic antidepressant 
UK  United Kingdom 
US  United States 
Vd  Volume of distribution 
VF  Ventricular fibrillation 
VT  Ventricular tachycardia 
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ABSTRACT 
Drug overdoses and poisonings are global health problems resulting in several thousands 
deaths annually. In out-of-hospital setting, one of the most common causes of death is an 
overdose of tricyclic antidepressant, such as amitriptyline. In the hospital, on the other hand, 
local anaesthetic systemic toxicity is one of the most feared and potentially a life-threatening 
complication. Both tricyclic antidepressants and local anaesthetics lack specific antidotes. 
However, as they all are lipophilic drugs, intravenously administered lipid emulsion has been 
suggested as a potential treatment for both intoxications. Originally, the proposed mechanism 
of action of lipid emulsion was a lipid sink that entraps lipophilic drugs and prevents their 
action in target tissues. Nowadays, lipid emulsion is a recommended treatment for local 
anaesthetic systemic toxicity in, for instance, the UK and the US in spite of the fact that its 
actual mechanisms of action and benefit remain uncertain. 
 
In the first study of this thesis, the incidence of local anaesthetic systemic toxicity and the 
adoption rates of lipid emulsion treatment in Finnish anaesthesia departments were elucidated 
(I). The other studies of this thesis investigate the efficacy of intravenously administered lipid 
emulsion in both local anaesthetic toxicity and amitriptyline. The effect on lidocaine induced 
central nervous system toxicity were studied in human volunteers (II). The effect of lipid 
emulsion on levobupivacaine intoxication in a situation simulating seizures (III), on the tissue 
distribution of amitriptyline (IV), and on mitochondrial respiration in bupivacaine cardiac 
toxicity (V) were studied in pigs. In each of these studies an assessment of the degree of the 
entrapment of the drug by intravenous lipid emulsion was included.  
 
The incidence of local anaesthetic systemic toxicity in Finland is low, only 0.7 per 10,000 
regional anaesthesias (I). Lipid emulsion treatment is adopted to less than half of the Finnish 
anaesthesia departments. In human volunteers, lipid emulsion does not affect the 
electroencephalography changes or the subjective symptoms caused by lidocaine. Lidocaine 
was also not entrapped into plasma, but its volume of distribution was slightly increased (II). 
In pigs, lipid emulsion has no effect on levobupivacaine intoxication which is exacerbated by 
acidosis and hypoxaemia as measured by reversing of electrocardiogram and haemodynamics 
from toxic changes (III). Levobupivacaine was also not entrapped into plasma. When lipid 
emulsion was infused in amitriptyline intoxication, amitriptyline was slightly entrapped into 
circulation and the brain amitriptyline concentration was reduced by 25% (IV). After higher 
lipid emulsion dose than recommended, recovery from bupivacaine cardiac toxicity was 
improved through peripheral vasoconstriction (V). Cardiac mitochondrial respiration was also 
slightly improved at the same time, and bupivacaine was slightly entrapped into plasma.  
 
To conclude, this is the first Finnish study to show that the incidence of local anaesthetic 
toxicity is very low: 0.7 per 10,000. Lipid emulsion can reduce amitriptyline brain 
concentration but has no effect on local anaesthetic systemic toxicity if used in clinically 
Abstract 
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recommended doses. If a higher dose is administered, lipid emulsion improves recovery from 
local anaesthetic toxicity through peripheral vasoconstriction in pigs. The safety of the higher 
dose to men remains, however, unknown. 
Tiivistelmä 
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TIIVISTELMÄ 
Lääkemyrkytykset ovat nykyisin maailmanlaajuinen ongelma aiheuttaen useita tuhansia 
kuolemantapauksia vuosittain. Amitriptyliinin, vanhan trisyklisen masennuslääkkeen, 
yliannostus on yksi tyypillisimmistä kuolemaan johtaneista syistä. Toisaalta 
paikallispuudutteiden aiheuttama puudutemyrkytys on ehkä niiden pelätyin ja potentiaalisesti 
hengenvaarallinen haittavaikutus. Trisyklisille masennuslääkkeille tai paikallispuudutteille ei 
ole olemassa spesifistä vasta-ainetta. Laskimoon annettavaa rasvaemulsiota on kuitenkin 
ehdotettu molempien lääkemyrkytysten hoidoksi. Alun perin vaikutusmekanismiksi ajateltiin 
”rasvakaivoa”, joka sitoisi rasvaliukoisia lääkemolekyylejä verenkiertoon ja estäisi niiden 
vaikutuksen kohde-elimissä. Rasvaemulsiota suositellaankin nykyisin puudutemyrkytyksen 
hoidoksi esimerkiksi Isossa-Britanniassa ja Yhdysvalloissa, vaikkei sen tehosta tai 
vaikutusmekanismeista ole varmuutta. 
 
Tämän väitöskirjan ensimmäisessä osatyössä selvitettiin puudutemyrkytysten yleisyys ja 
kuinka laajasti rasvaemulsiohoito on levinnyt Suomen anestesiaosastoille (I). Muissa 
osatöissä selvitetään rasvaemulsion tehoa sekä puudute- että amitriptyliinimyrkytyksissä. 
Rasvaemulsion tehoa lidokaiinin aiheuttamiin keskushermosto-oireisiin tutkittiin 
vapaaehtoisilla koehenkilöillä (II). Sen vaikutusta kouristuksia jäljittelevään tilanteeseen 
levobupivakaiinimyrkytyksessä (III), amitriptyliinin jakaantumiseen (IV) ja mitokondrioiden 
soluhengitykseen bupivakaiinimyrkytyksessä (V) tutkittiin porsasmallissa. Kaikissa näissä 
tutkimuksissa selvitettiin myös rasvaemulsion kykyä sitoa lääkkeitä itseensä verenkierrossa.  
 
Puudutemyrkytykset ovat harvinaisia Suomessa: vain 0,7 tapausta 10.000 paikallispuudutusta 
kohden. Rasvaemulsio oli otettu osaksi puudutemyrkytysten hoitoa vajaassa puolessa Suomen 
anestesiaosastoista (I). Rasvaemulsiolla ei ollut vaikutusta vapaaehtoisilla koehenkilöillä 
lidokaiinin aiheuttamiin aivosähkökäyrämuutoksiin tai subjektiivisiin oireisiin (II). Lidokaiini 
ei myöskään ollut sitoutunut rasvaemulsioon, vaikkakin sen jakaantumistilavuus hieman 
kasvoi. Porsasmallissa rasvaemulsiolla ei ollut vaikutusta elimistön happamuuden eikä 
hapenpuutteen pahentamassa levobupivakaiinimyrkytyksessä sydänsähkökäyrän tai 
verenkierron toipumiseen myrkytyksestä (III). Levobupivakaiini ei myöskään sitoutunut 
rasvaemulsioon. Kun rasvaemulsiota annettiin hoidoksi amitriptyliinimyrkytykseen, osa 
amitriptyliinistä sitoutui siihen ja aivojen amitriptyliinipitoisuus laski 25 % (IV). 
Hoitosuosituksia suuremman rasvaemulsioannoksen antaminen tehosti toipumista 
bupivakaiinin aiheuttamasta verenkierron lamasta supistamalla ääreisverenkiertoa (V). Myös 
sydämen mitokondrioiden soluhengitys tehostui hieman ja bupivakaiini sitoutui osittain 
rasvaemulsioon verenkierrossa.  
 
Yhteenvetona voidaan todeta, että tämä oli ensimmäinen suomalainen tutkimus, jossa 
osoitettiin puudutemyrkytyksen olevan harvinainen komplikaatio: alle 1 tapaus 10.000 
puudutusta kohden. Antamalla rasvaemulsiota voidaan alentaa aivojen 
Tiivistelmä 
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amitriptyliinipitoisuutta, mutta puudutemyrkytyksen oireisiin sillä ei ole vaikutusta 
hoitosuosituksen mukaisena annoksena. Toisaalta käyttämällä suurempaa annosta voidaan 
ainakin porsasmallissa tehostaa toipumista puudutemyrkytyksestä aiheuttamalla verenkierron 
supistuminen. Suuremman rasvaemulsioannoksen turvallisuudesta ihmisillä ei kuitenkaan ole 
tietoa. 
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INTRODUCTION  
Today, drug overdoses are a global problem 
thought to have caused up to 183,000 deaths 
among working aged persons worldwide in 
2012 (United Nations Office on Drugs and 
Crime, 2014). In Finland, every year drug 
overdoses cause more than 1,000 deaths 
(Vuori et al., 2012). Self-poisonings are not 
the only cause of drug related emergencies 
or deaths; iatrogenic drug administration for 
therapeutic purposes can cause life-
threatening situations and even deaths. For 
example, local anaesthetics are mainly used 
to produce local anaesthesia but their 
systemic effects can be life threatening. This 
local anaesthetic systemic toxicity or 
intoxication (LAST) is a consequence of an 
unintentional injection of local anaesthetic 
directly into the bloodstream (de Jong, 
1978), or of the absorption of the local 
anaesthetic after administration of an 
overdose which may have been used in 
epidural or brachial plexus blocks for 
surgical anaesthesia (Di Gregorio et al., 
2010). Untreated, the complication may be 
fatal (Lee et al., 2008). 
 Next after opioids, the drug most 
commonly associated with deaths by 
overdose is the tricyclic antidepressant 
(TCA) amitriptyline (Vuori et al., 2012). 
Typically these poisonings happen to 
persons of working age and are intentional 
(Peiris-John et al., 2014; Vuori et al., 2012). 
Unfortunately, the cause of death in these 
suicides is typically prescription medication 
(Sinyor et al., 2012). Even though almost 
90% of poisoning deaths occur outside of 
hospital (Bjornaas et al., 2010), 
hospitalisations due to drug overdoses are 
also an increasing problem, with over 100 
hospitalisations per 100,000 persons per 
year in some parts of the United States (US) 
(Slavova et al., 2014). Fortunately, if the 
patient is reached in time the prognosis is 
usually good, as up to 94% of the 
hospitalised poisoning patients can be 
discharged within the next 24 hours, and 
only a minority needs treatment in an 
intensive care unit (Lapatto-Reiniluoto et 
al., 1998). 
 Local anaesthetics and TCAs are both 
lipophilic drugs (ChemSpider, 2015) 
without specific antidotes. The treatment of 
both LAST and TCA poisoning has been 
symptomatic. In case of LAST, the 
treatment includes securing the airways, 
normalisation of blood pH, treating seizures, 
managing haemodynamic instability and 
treating electrocardiogram (ECG) 
abnormalities possibly with sodium 
bicarbonate (McLeod et al., 2008). 
Treatment of TCA poisonings is quite 
similar, except that for preventing 
gastrointestinal absorption of TCA, 
activated charcoal is administered 
intragastrically (Body et al., 2011). 
 The hypothesis that life-threatening 
poisonings caused by lipophilic substances 
could be treated with a large dose of 
intravenous (i.v.) lipid emulsion originated 
when Weinberg and colleagues (1998) 
noted that pre-treatment with intravenous 
lipid emulsion increased the bupivacaine 
dose required to produce asystole in rats. 
Eight years later, the first case reports of 
treating LAST with lipid emulsion appeared 
(Litz et al., 2006; Rosenblatt et al., 2006) 
and eventually the Association of 
Anaesthetists of Great Britain and Ireland 
(AAGBI) and the American Society of 
Introduction 
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(ASRA) decided to recommend intravenous 
lipid emulsion for the treatment of LAST 
(Cave et al., 2010; Neal et al., 2010). Later, 
animal studies (Harvey and Cave, 2007) and 
case reports (Engels and Davidow, 2010) of 
lipid rescue of also TCA poisoning were 
published. As a consequence, lipid emulsion 
is now added as a possible adjuvant 
treatment of TCA poisoning (Body et al., 
2011). After more than 15 years of the first 
lipid rescue studies and more than 60 case 
reports, the lipid rescue is not evidence 
based and the possible mechanisms of 
action of lipid emulsion still remain 
unresolved (Harvey and Cave, 2014; 
Tucker, 2014). 
 Therefore, the aim of this thesis was 
to figure out the incidence of LAST in 
Finland and to investigate the effects of 
lipid emulsion in the treatment of LAST and 
amitriptyline poisonings. It was 
hypothesised that lipid emulsion could 
alleviate central nervous system (CNS) 
toxicity of local anaesthetics, reduce 
amitriptyline concentration in tissues, and 
improve recovery of bupivacaine cardiac 
toxicity by increasing the mitochondrial 
respiration. 
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REVIEW OF THE LITERATURE 
LOCAL ANAESTHETICS  
The development of local anaesthesia dates 
back to the middle of the 19th century when 
German chemist Niemann (1860) managed 
to isolate the active ingredient of coca leaf 
naming it cocaine. The modern age of local 
anaesthesia began, however, in the 1940s 
when Swedish chemist Löfgren with his 
group synthesised the first modern local 
anaesthetic, lidocaine (Löfgren and 
Lundqvist, 1947), which was introduced 
into clinical use by the end of the decade 
(Gordh, 1949). The development of modern 
local anaesthetics continued in Sweden, and 
long acting local anaesthetics mepivacaine 
and bupivacaine, which are still in use, were 
synthesised during the next decade (af 
Ekenstam et al., 1957) and soon used also 
clinically. Even though synthesised at the 
same time as other long acting local 
anaesthetics, the less toxic ropivacaine and 
levobupivacaine were introduced into 
clinical practise much later, in 1996 and by 
the beginning of 2000s, respectively, being 
the newest local anaesthetics (Whiteside and 
Wildsmith, 2001). Today, local anaesthetics 
are widely used at every level of our health 
care system. In primary health care, the 
most used local anaesthetic is lidocaine 
(Figure 1) to provide anaesthesia, for 
example, for small surgical procedures, 
 
Figure 1. Chemical structure of lidocaine. 
such as removal of a naevus. Long acting 
local anaesthetics, such as bupivacaine 
(Figure 2), can provide sufficient 
anaesthesia even for surgery and childbirth. 
Unfortunately, not all physicians using local 
anaesthetics respect, or possibly even are 
aware of, the potential risks of local 
anaesthetics (Rao et al., 1999; Sagir and 
Goyal, 2014; Scherrer et al., 2013). 
Figure 2. Chemical structure of 
bupivacaine. 
 
Pharmacology 
Local anaesthetics are amine molecules that 
can be divided into esters (procaine type; 
Figure 3) and amides (lidocaine type; see 
Figure 1) according to the binding type 
between the lipophilic and hydrophilic 
portions. Both types of local anaesthetics 
are lipophilic and weak bases with a pKa 
(pH at which molecules are half-
dissociated) near 8 (Table 1). Therefore, in 
 
  
Figure 3. Chemical structure of procaine. 
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an acidic environment the molecules 
become ionised which increases their 
hydrophilicity (Figure 4). To increase their 
hydrophilicity and solubility for clinical use, 
local anaesthetics are typically formulated 
as hydrochloride salts. 
 The main mechanism of action of 
local anaesthetics is the blockade of voltage-
gated sodium channels (Figure 5) which are 
situated within the cell membrane of, for 
instance, axons and cardiomyocytes (Hille, 
1977). The presence of a local anaesthetic 
blocks the ion channel pore and prevents 
membrane depolarisation by preventing the 
fast flow of Na+ ions into the cell (Catterall, 
2012). The binding site in these sodium 
channels lies on the inner side of the cell 
membrane (Catterall, 2012). To reach their 
binding site the local anaesthetics have to 
cross the cell membrane in the lipophilic 
uncharged form. After entering the cell, 
local anaesthetics become ionised due to the 
acidic intracellular environment and are able 
to bind to the sodium channel (Hille, 1977). 
At that time, the channels are preferably in 
either open or inactive state, and therefore, 
accessible through the open activation gate 
(Catterall, 2012; Hille, 1977); in the resting 
state of sodium channel the affinity of the 
local anaesthetic to the channel is weaker 
(because the activation gate is closed) with 
the exception of bupivacaine which slowly
 
Table 1. Physicochemical and some pharmacokinetic properties of local anaesthetics 
 pKa at 
25°C 
LogD LogP Vd (l kg–1) Plasma 
protein 
binding (%) 
Approximate 
anaesthesia 
duration (min) 
Esters       
Chloroprocaine 9.3 1.15 2.93 0.50 – 45 
Cocaine 8.6 1.22 3.08 1.96 92 – 
Amides       
Lidocaine 7.8 1.80 1.66 1.30 70 100 
Prilocaine 8.0 1.33 1.74 2.73 55 100 
Mepivacaine 7.9 1.40 2.04 1.2 80 100 
Ropivacaine 8.2 2.32 3.11 0.84 94 150 
Bupivacaine 8.2 2.68 3.64 1.02 95 175 
Levobupivacaine 8.2 2.68 3.64 0.9 95 175 
pKa, dissociation constant (Strichartz et al., 1990; Wiczling et al., 2006); logD, logarithm of predicted octanol:water 
partition coefficient at physiological pH (ChemSpider, 2015); logP, logarithm of predicted octanol:water partition 
coefficient at pH 7 (ChemSpider, 2015); Vd, volume of distribution (Chow et al., 1985; Rosenberg et al., 2004); protein 
binding (Bachmann et al., 1990; Burm et al., 1994; Edwards and Bowles, 1988; Lee et al., 1989; Tucker and Mather, 
1975); anaesthesia duration of rat sciatic nerve blocking (Mather and Tucker, 2008). 
 
Figure 4. Ionisation of lipophilic lidocaine base into its hydrophilic acid form. 
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Figure 5. Structure and normal cycle of voltage-gated sodium channels during action 
potential: closed channel opens during action potential allowing rapid Na+ influx, but rapidly 
inactivates ending Na+ flow (above). On the left and below, the local anaesthetic base (L) 
permeates the cell membrane and ionises in the cytoplasm, after which it is able to bind to a 
receptor site in the pore of the open or inactivated channel. In the resting state, the activation 
gate is closed, which prevents the local anaesthetic from binding to the receptor site. The 
unionised form (especially bupivacaine) can also affect the channel in its resting state 
through the lipid phase of the cell membrane (Catterall, 2012). Modified from Mantegazza et 
al. (2010). 
 
dissociates from the resting state channels 
(Clarkson and Hondeghem, 1985). In 
addition to voltage-gated sodium channels, 
local anaesthetics also interact with several 
other types of ion channels and G-protein 
receptors (Hollmann et al., 2001; Komai 
and McDowell, 2001). 
 The absorption rate of local 
anaesthetic into the bloodstream depends on 
the drug itself, the dosage, addition of 
vasoconstrictor, and the site of injection, its 
vascularity and content of fat capable to 
bind the drug (Tucker and Mather, 1979). 
Typically, the absorption rate, from highest 
to lowest, is similar between different 
agents: intercostal, caudal, epidural, brachial 
plexus, and sciatic/femoral block (Tucker, 
1986). After systemic absorption local 
anaesthetics are mostly bound to serum 
proteins, primarily to α1-acid glycoprotein 
but also to albumin (Mazoit and Dalens, 
2004). The fraction of unbound drug 
increases with increasing total drug 
concentration (Tucker et al., 1970), as the 
drug binding proteins become saturated. The 
pharmacological activity, including the 
systemic toxicity, of a drug is mainly related 
to its unbound concentration (Tucker and 
Mather, 1975), which varies from 
approximately 5 to 45% between the local 
anaesthetics (see Table 1, page 16). 
 Only a small proportion of amide 
local anaesthetic agents are excreted 
unchanged (Boyes, 1975; Keenaghan and 
Boyes, 1972). The metabolism takes place 
mainly in the liver by the cytochrome P450-
dependend mixed function oxidase system 
(Imaoka et al., 1990; Oda et al., 1995). 
Closed (resting) Open InactivatedL+H
+ LH+
L+H+ LH+
LH+
Extracellular space
pH ~7.4
Cytosol
pH <7.4
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After metabolism the different metabolites 
are then secreted into urine in varying 
quantities (Boyes, 1975). Urine pH 
acidification increases the amount of 
excretion of unchanged agents (Eriksson, 
1966; Friedman et al., 1982). Amide local 
anaesthetics have relatively short terminal 
elimination half-lives varying from 1.6 h for 
lidocaine to 2.7 h for bupivacaine (Table 2). 
In contrast to amide type local anaesthetics, 
the ester type local anaesthetics are rapidly 
hydrolysed by plasma 
pseudocholinesterases, red cells and liver 
esterases (Tucker, 1986). Therefore, their 
half-lives are extremely short: the half-life 
of chloroprocaine, for instance, in whole 
blood is only 21–25 s in vitro (O'Brien et 
al., 1979). As the hydrolysis begins even 
before the distribution phase, they are 
relatively safe to use in large doses without 
a substantial risk of LAST (Rosenberg et 
al., 2004). Similarly to amide type agents, 
also the metabolites of ester type local 
anaesthetics are excreted into urine (O'Brien 
et al., 1979).  
 
Local anaesthetic systemic toxicity 
Local anaesthetic systemic toxicity, or 
LAST, is the systemic effect of a too high 
local anaesthetic blood concentration (de 
Jong, 1978). The typical reason for this high 
circulating concentration is an unintentional 
intravascular injection. Other mechanisms 
are rapid absorption from a highly 
vascularised injection site or the use of an 
excessive dose of local anaesthetic. Such 
potentially toxic cumulative doses occur, for 
example, when continuous local anaesthetic 
infusions are used in patients with slow drug 
metabolism and/or saturated metabolic 
pathways, or due to technical dosing errors 
(Whiteman and Kushins, 2014). Chronic 
diseases, such as renal failure, may alter the 
pharmacokinetics of local anaesthetics by 
increasing their uptake and decreasing their 
clearance (Pere et al., 2003). The toxic 
effects result from too high local anaesthetic 
concentrations, and therefore, too much ion 
channel blockade in the central nervous 
system (CNS) and heart. As mentioned 
previously, the free, pharmacologically 
active, fraction increases as the local 
anaesthetic concentration rises in the 
circulation. Therefore, the toxic effects do 
not appear linearly, since the active fraction 
is larger at higher concentrations (Tucker 
and Mather, 1975). 
 
 
Table 2. Elimination of the clinically most important amide local anaesthetics 
 Cl (l min–1) EH t1/2 (h) MBRT (h) CYP 
Lidocaine 0.95 0.65 1.6 1.6 1A2, 3A4 
Mepivacaine 0.78 0.52 1.9 1.8 ? 
Ropivacaine 0.73 0.49 1.9 1.4 1A2, 3A4 
Bupivacaine 0.58 0.38 2.7 2.1 3A4, 2C19, 2D6 
Levobupivacaine 0.47 0.67 1.8 2.2 1A2, 3A4 
Cl, systemic clearance; EH, estimated hepatic extraction ratio; t1/2, terminal elimination half-life; CYP, metabolising 
cytochrome P450 enzymes; MBRT, mean body residence time. (Data derived from: Bargetzi et al., 1989; Ekström and 
Gunnarsson, 1996; Foster and Markham, 2000; Gantenbein et al., 2000; Mather and Tucker, 2008). 
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 The first signs of LAST include 
numbness, lightheadedness and tinnitus 
(Foldes et al., 1960; Scott, 1975; 1986). If 
the systemic local anaesthetic concentration 
rises, visual disturbances, slurring of speech 
and muscle twitches follow (Foldes et al., 
1960; Scott, 1975; 1986). With even higher 
concentrations, local anaesthetics cause 
tonic-clonic seizures and coma (Scott, 1986; 
Usubiaga et al., 1966). Eventually, apnoea 
and cardiac depression with arrhythmias 
follow (Kotelko et al., 1984; Scott, 1986). 
The reported incidence of LAST in the past 
15 years has been 0.6 to 3.5 per 10,000 
procedures after excluding spinal 
anaesthesias (Auroy et al., 2002; Barrington 
and Kluger, 2013; Ecoffey et al., 2014; Sites 
et al., 2012), and the majority of cases has 
been central nervous system intoxications. 
 The cardiac effects of bupivacaine 
differ from other local anaesthetics. 
Lidocaine both enters and exits the 
cardiomyocytes and sodium channel pores 
rapidly, and therefore, the myocytes recover 
quickly from the ion channel blockade 
during diastole. This rapid dissociation 
during diastole means that the cardiotoxic 
effects of local anaesthetics are mitigated by 
a lower heart rate. Bupivacaine, however, 
dissociates slowly from the resting sodium 
channels and also exits the cell more slowly 
(Clarkson and Hondeghem, 1985). Thus, the 
cardiac effects of bupivacaine accumulate 
even at lower heart rates, while the effects 
of lidocaine can be seen only at high heart 
rate (Clarkson and Hondeghem, 1985). 
Bupivacaine has also more potent 
depressive effect on atrioventricular node 
conduction (Komai and Rusy, 1981), 
velocity of action potentials and myocardiac 
contractility (Shibuya et al., 1993) than, for 
instance, lidocaine (Courtney, 1984). 
Levobupivacaine, the less cardiotoxic ‘S(–)’ 
enantiomer of bupivacaine, has less affinity 
for cardiac sodium channels and the 
dissociation is faster than with 
dextrobupivacaine (McClellan and Spencer, 
1998), and has, therefore, partially replaced 
the racemic bupivacaine in clinical use 
(Whiteside and Wildsmith, 2001). 
 Part of the local anaesthetic toxicity 
has been explained by their effects on the 
cardiac mitochondria. In isolated 
mitochondria, high concentrations of 
bupivacaine inhibit oxidative 
phosphorylation, and decrease the 
production of adenosine triphosphate (ATP) 
(Cela et al., 2010; Sztark et al., 1998). The 
main depressive effect on the mitochondrial 
respiration is the inhibition of complex I 
(nicotinamide adenine dinucleotide 
[NADH] dehydrogenase) of the respiratory 
chain (Sztark et al., 1998). 
 In clinical setting of severe LAST, 
the seizures turn the patient rapidly 
hypoxaemic, hypercapnic and acidotic 
resulting in both respiratory and metabolic 
acidosis (Rosenberg et al., 1983). The 
acidosis exacerbates the local anaesthetic 
toxicity (Porter et al., 2000), as the free drug 
concentration rises (Burney et al., 1978) and 
the drug molecules are trapped inside 
cardiomyocytes in their ionised form 
(Tucker and Mather, 1975). The same 
exacerbation of toxicity can be seen also 
after hypoxaemia (Heavner et al., 1992). 
 
TRICYCLIC ANTIDEPRESSANTS  
TCAs were introduced for the treatment of 
depression in the late 1950s, imipramine 
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being the first one (Azima, 1959). Later, 
newer TCAs, such as amitriptyline (Figure 
6) and nortriptyline, have mainly replaced 
imipramine in clinical practise. In addition 
to depression, the indications for TCA 
prescription have extended to involve not 
only several psychiatric disorders but also, 
for instance, pain syndromes, fibromyalgia 
and insomnia (Woolf et al., 2007). 
Nowadays, TCAs are not, however, 
considered as a first line treatment for 
depression anymore (Depression: Current 
Care Guideline 2014). In chronic pain 
syndromes (e.g., neuropathic pain and 
fibromyalgia), instead, for example 
  
 
 
Figure 6. Chemical structure of 
amitriptyline. 
amitriptyline has still an important role 
(Finnerup et al., 2005; Moore et al., 2012).
 According to the sales numbers in 
Finland in 2013 (Finnish Medicines 
Agency, 2013), approximately 4 persons out 
of 1000 used some TCA, amitriptyline 
being the most used, at its average 
maintenance dose (defined daily dose 
[DDD] of 4.26 per 1000 persons). During 
the last years, the consumption rate of TCAs 
has been rather stable. In addition to 
amitriptyline being the most used TCA, it 
has been one of most common causes of 
fatal poisonings in Finland for the last 
decade (Vuori et al., 2009; 2012). 
 
Pharmacology 
TCAs are tertiary amines with two methyl 
groups attached to a nitrogen atom. They are 
lipophilic, and therefore, rapidly absorbed 
from the gastrointestinal tract, after which 
they are also quite rapidly demethylated to 
the active secondary amines. From the 
bloodstream they are distributed into tissues 
(volumes of distribution vary from 
approximately 10 to 50 l kg–1 between 
different TCAs). The physicochemical and 
some pharmacokinetic properties of TCAs 
are presented in more detail in Table 3.
 
Table 3. Physicochemical and some pharmacokinetic properties of tricyclic antidepressants 
 pKa at 25°C LogD LogP Vd (l kg–1) Plasma 
protein 
binding (%) 
Amitriptyline 9.4 2.96 4.92 8.9 95 
Nortriptyline 10.1 2.28 5.65 19.1–34.6 92.5 
Clomipramine 9.3 3.31 5.39 11.9 97.25 
Doxepin 9.0 2.50 3.86 89.6 79.6 
Imipramine 9.5 2.68 4.80 11.5–17.5 85 
pKa, dissociation constant (Embil and Torosian, 1982; Shalaeva et al., 2008); logD, logarithm of predicted octanol:water 
partition coefficient at physiological pH (ChemSpider, 2015); logP, logarithm of predicted octanol:water partition 
coefficient at pH 7 (ChemSpider, 2015); Vd, volume of distribution (Scoggins et al., 1980); plasma protein binding (Ferner, 
2008; Virtanen et al., 1982).  
N
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 The primary antidepressive 
mechanism of action of TCAs is the 
prevention of noradrenaline, but also 
serotonin, uptake at nerve terminals 
increasing their concentration in the 
synaptic cleft (Ballinger and Feely, 1983; 
Tatsumi et al., 1997). TCAs have, however, 
several other effects that may be unwanted, 
such as anticholinergic effects (El-Fakahany 
and Richelson, 1983), or blockade of α1-
adrenoceptors (U'Prichard et al., 1978), 
histamine H1 receptors (Richelson, 1978), or 
γ-aminobutyric acid receptors (Malatynska 
et al., 1988). In addition to these receptors, 
they also block neural sodium and calcium 
channels (Ishii and Sumi, 1992; Lavoie et 
al., 1990), likely by binding to the same 
receptor site as local anaesthetics (Nau et 
al., 2000). 
 As mentioned above, the enteral 
absorption of TCAs is marked, in some 
cases even better than parenteral absorption 
after, for example, intramuscular 
administration (Scoggins et al., 1980). After 
absorption, they undergo first-pass 
metabolism by cytochrome P450 (CYP) 
isoenzymes (mainly by CYP2D6 and 
CYP2C19) which determines the 
availability of the active metabolites, e.g. E-
10-OH-nortriptyline, the active metabolite 
of both amitriptyline and nortriptyline 
(Rudorfer and Potter, 1999). The 
metabolism of TCAs is also dependent on 
the huge polymorphism of CYP2D6 (Zhou, 
2009) but also that of CYP2C19 (Desta et 
al., 2002), which affect the drug responses. 
In the bloodstream, the TCAs are bound to 
plasma proteins, such as albumin and 
lipoproteins but also to α1-acid glycoprotein 
(Routledge, 1986), to a great extent, and 
hence the fraction of free drug is usually 
less than a quarter of the total concentration 
(Molnar and Gupta, 1980; Scoggins et al., 
1980). In addition to marked protein 
binding, TCAs distribute into tissues, in 
which the concentration may be much 
higher than in blood, and as lipophilic drugs 
they easily cross the blood-brain barrier 
(Scoggins et al., 1980). 
 TCAs are demethylated and 
metabolised very efficiently mainly into 
hydroxy compounds through hydroxylation 
followed by glucuronide coupling in the 
liver (Scoggins et al., 1980). These 
metabolites are then secreted into urine 
(Molnar and Gupta, 1980). 
 
Tricyclic antidepressant poisoning 
TCAs are used as enteral drugs so the TCA 
poisoning is a consequence of either 
intentional or unintentional ingestion of 
large dose of a TCA alone or along with 
other medication or alcohol. An overdose of 
TCAs markedly changes their 
pharmacokinetics. The delaying of gastric 
emptying may delay absorption from 
gastrointestinal tract, the final elimination is 
delayed due to notable enterohepatic 
recirculation and saturation of metabolising 
enzymes, and the free fraction of the drug 
may increase due to acidosis which is a 
result of respiratory depression (Jarvis, 
1991). 
 The first cardiovascular effect of 
TCA poisoning is sinus tachycardia due to 
the reduced noradrenaline uptake from 
synaptic clefts and anticholinergic effects 
(Kerr et al., 2001; Taylor and Braithwaite, 
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1978). In a more serious poisoning, they 
delay the depolarisation in myocardium and 
conduction system by inhibiting sodium 
channels (Brennan, 1980). The inhibition of 
cell depolarisation can be seen as 
prolongation of ECG conduction times, such 
as widening of QRS complex and 
lengthening of QT interval (Liebelt et al., 
1997). These ECG abnormalities also 
predict cardiac arrhythmias and seizures, 
and usually persist regardless of patient’s 
clinical improvement (Liebelt et al., 1997). 
The patient’s condition can also deteriorate 
later after apparent stabilisation (Levine, 
Brooks, et al., 2012). Similarly, the 
inhibition of sodium current can result in a 
depressed contractility in the heart (Kerr et 
al., 2001; Taylor and Braithwaite, 1978). 
Together with the cardiac effects, the 
blockade of peripheral α1-adrenoceptors 
leads to vasodilation, and hypotension (Kerr 
et al., 2001; U'Prichard et al., 1978). 
 In addition to cardiovascular effects, 
TCA poisoning may provoke seizures 
(Taboulet et al., 1995). The lowered seizure 
activity in serious poisonings is considered 
to stem from the antagonism of inhibitory γ-
aminobutyric acid receptors in the CNS 
(Malatynska et al., 1988). Both CNS and 
cardiac toxicity, however, is rather difficult 
to predict from the ingested dose due to 
altered pharmacokinetics (Jarvis, 1991). 
 The anticholinergic effects are 
common, even at non-toxic doses, and may 
cause, for instance, ileus but rarely are 
serious. There is, however, a possibility of 
even fatal complications, such as toxic 
megacolon and perforation (Ross et al., 
1998). 
 
INTRAVENOUS LIPID EMULSION  
Commercial lipid emulsions were originally 
developed in the 1960s to be used as a 
component of parenteral nutrition (MacFie, 
1999). The lipids are presented as dispersed 
particles comparable in the size of 
chylomicrons (200–400 nm). The 
compositions of Intralipid®, one of the most 
commonly used lipid emulsion, is presented 
in Table 4. Critically ill patients, for 
example, in intensive care units require 
essential fatty acids that are the primary 
component of lipid emulsions (Calder et al., 
2010). The lipid emulsions are composed of 
triglyceride-rich particles which are 
 
 
Table 4. Compositions of 20% Intralipid® (Fresenius Kabi AB, 2013; Skeie et al., 1988; 
Washington et al., 1993) 
Soya bean oil 200 mg l–1 
Linoleic acid (C18:2) 44–62% 
Oleic acid (C18:1) 19–30% 
Palmitic acid (C16:0) 7–14% 
Linolenic acid (C18:3) 4–11% 
Stearic acid (C18:0) 1.4–5.5% 
Arachidinoc acid (C20:4) ∼0.6% 
Egg yolk phosphatides  12 mg l–1 
Glyserin 22.5 mg l–1 
Particle size 346±18 nm 
pH 8 (range 6 to 8.9) 
Osmolality 350 mOsmol kg–1 (260 mOsmol l–1) 
Total caloric value 2.0 kcal ml–1 
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stabilised by phospholipids (Carpentier and 
Dupont, 2000). The triglycerides are 
typically vegetable oil based, or fish oil 
based in newer compounds, with a typical 
concentration of 10 to 30% (Carpentier and 
Dupont, 2000).  
 The fatty acids, derived from lipid 
emulsions, do not function only as nutrients 
but they also have an important role on 
immune modulation as they effect cell 
membrane fluidity, production of bioactive 
mediators and cell signalling (Wanten and 
Calder, 2007). Even gene expression and 
increment in lymphocyte apoptosis are 
modulated by fatty acids (Wanten and 
Calder, 2007). Infusion of especially soya 
bean-based lipid emulsions seem to 
associate also with high blood levels of ω-6 
polyunsaturated fatty acids and arachidonic 
acid which may lead to production of 
proinflammatory, but also vasoconstrictive, 
prostaglandins and thromboxanes (Calder et 
al., 2010). 
 Lipid emulsions are not utilised 
solely as nutritional solutions. As some 
drugs are not water-soluble but are desired 
to be administered i.v., lipid emulsion offers 
a suitable vehicle for such administration 
(Tamilvanan, 2004). Commercially 
available drugs dissolved in lipid emulsion 
include, for instance, propofol, diazepam, 
etomidate and dexamethasone (Tamilvanan, 
2004). 
 
LIPID RESCUE 
Treatment of severe intoxications with 
intravenous lipid emulsion, or lipid rescue, 
has been developed mainly during the last 
15 years. The basis of lipid rescue has been 
pharmacokinetic interactions between lipid 
emulsion and lipophilic drugs, and 
therefore, alleviation of toxicity symptoms. 
At the moment it is a recommended 
treatment of LAST, for instance, in the 
United Kingdom (UK) and the US (Cave et 
al., 2010; Neal et al., 2012). In the 
international literature, lipid rescue has also 
been proposed as a potential treatment of 
several other drug poisonings (Cave and 
Harvey, 2014). 
 
Background 
The first study of interactions between lipid 
emulsion and lipophilic drug, thiopental, 
was published soon after the introduction of 
the first commercially available lipid 
emulsion (MacFie, 1999; Russell and 
Westfall, 1962). Over the following 
decades, only few studies were published on 
the topic (Krieglstein et al., 1974; Minton et 
al., 1987; Straathof et al., 1984). Even 
though the idea of treating poisonings of 
lipophilic drugs with intravenous lipid 
emulsion was already invented, it did not 
convince the researchers at that time 
(Minton et al., 1987). 
 The birth of lipid rescue can be laid 
in the year 1998 when Weinberg and 
colleagues (1998) published the first reports 
suggesting that lipid rescue would actually 
work. They had managed to reduce 
bupivacaine toxicity by treating or pre-
treating rats with intravenous lipid 
emulsion. Since then, several animal studies 
and human case reports have been published 
on lipid rescue of various drug intoxications 
(Bartos and Knudsen, 2013; Jamaty et al., 
2010). The evidence supporting lipid rescue 
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is, however, based almost entirely on animal 
studies and published case reports. After the 
work of Weinberg’s group, the first and 
only human studies, without any notable 
differences between the treatment with lipid 
emulsion and the control treatment, were 
published in 2012 (Litonius, Tarkkila, et al., 
2012; Taftachi et al., 2012). 
 
Mechanisms of action  
Originally, the mechanism of action of lipid 
rescue was proposed to be the formation of 
a ‘lipid sink’: a lipophilic plasma phase that 
entraps lipophilic drug agents into itself, and 
therefore, prevents their action in target 
tissues, or even draws already distributed 
molecules back into the bloodstream 
(Weinberg et al., 1998). According to the 
lipid sink theory, the lipophilic drugs would 
sequester inside the triglyceride oil droplets 
in bloodstream depending on their 
lipophilicity (Damitz and Chauhan, 2015). 
This mechanism was the same that was 
considered ineffective a decade earlier 
(Minton et al., 1987) but now the lipid sink 
theory was considered the main mechanism 
of action (Neal et al., 2010; Weinberg, 
2008), mainly because lipid emulsion 
seemed to reverse toxicity caused by various 
lipophilic drugs, including β-blockers (Cave 
et al., 2006), calcium channel blockers 
(Bania et al., 2007), and TCAs (Harvey and 
Cave, 2007). Later this theory gained more 
support as lipid emulsions markedly 
entrapped various drugs, including 
lipophilic local anaesthetics, in vitro (Laine 
et al., 2010; Lokajová et al., 2012; Mazoit et 
al., 2009). In vivo, however, lipid emulsion 
entrapped only extremely lipophilic drugs, 
such as amiodarone (approximately 10,000 
times more lipophilic than bupivacaine) 
(Niiya et al., 2010) or amitriptyline 
(approximately 100 times more lipophilic 
than bupivacaine) (Litonius et al., 2012a). It 
seemed that local anaesthetics may not be 
lipophilic enough to be entrapped by lipid 
emulsion (Litonius et al., 2012b; Litonius, 
Tarkkila, et al., 2012). Very high doses of 
lipid emulsion, i.e., higher than those 
recommended in the published guidelines, 
can affect the distribution of bupivacaine in 
rats and possibly increase the metabolism by 
increasing the shunting into liver (Shi et al., 
2013). 
 Lipid emulsion has been studied 
mainly as a treatment for cardiac toxicity, 
and because lipids are heart’s preferred 
energy substrates, another theory is that 
large lipid dose could reverse the inhibition 
of fatty acid metabolism in cardiac 
mitochondria (Stehr et al., 2007). This 
metabolism theory gained more support as 
Partownavid and colleagues (2012) showed 
that inhibition of fatty acid oxidation in 
cardiac mitochondria prevented also the 
resuscitative effect of lipid emulsion in rats. 
These metabolic, or other direct cardiac, 
effects may be even more important than the 
lipid sink because in more recent studies 
very high doses of lipid emulsion have 
caused a rise in arterial blood pressure, heart 
rate and carotid blood flow in rats, possibly 
through inotropic and lusitropic mechanisms 
(Fettiplace et al., 2013; Fettiplace, Akpa, et 
al., 2014). 
 Lipid emulsion may also have 
different than metabolic effects on heart. In 
tissue culture, free fatty acids reduce the 
degree of bupivacaine sodium current 
inhibition (Mottram et al., 2011) supporting 
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a theory that lipid emulsion may also affect 
the binding of local anaesthetics in sodium 
channels. In addition, cardiac calcium 
channels have been found to be activated by 
several long-chain fatty acids, e.g. oleic, 
linoleic and palmitic acid, at concentrations 
of 3 to 30 mM (Huang et al., 1992). These 
fatty acids are the main components of 
commercial lipid emulsions, such as 
Intralipid® (see Table 4, page 22). 
 It is not yet known which of the 
suggested mechanisms of action of lipid 
emulsion are the main contributors in the 
treatment (Harvey and Cave, 2014; Tucker, 
2014). However, it seems that the original 
lipid sink will not explain the reversal of 
toxicity alone (Tucker, 2014) – at least in 
case of LAST. 
 
Lipid rescue human study in local 
anaesthetic systemic toxicity  
At the moment, there is only one 
prospective human study on the effect of 
lipid rescue in LAST. Litonius and 
colleagues (2012) showed in a randomised 
cross-over study that lipid emulsion infusion 
decreased the context-sensitive half-time 
(t1/2) of total bupivacaine concentration by 
44%. There were, however, no entrapment 
of bupivacaine, or no differences in 
concentrations or context-sensitive t1/2 of 
free bupivacaine objecting the lipid sink 
theory. 
 
Lipid rescue animal studies in local 
anaesthetic systemic toxicity  
At the moment, there are at least 37 
randomised controlled animal studies on the 
lipid rescue in LAST (Table 5). These 
studies include also three cell studies, and 
nine studies on rat aorta or heart. In addition 
to different models, there is a large variation 
in treatment, especially in dosing of lipid 
emulsion, and in outcome measures between 
the studies. 
 In 1998, Weinberg and colleagues 
(1998) published the first randomised 
controlled animal study on treatment of 
LAST with intravenous lipid emulsion. 
They showed that pre-treatment with 
different lipid emulsions increased the lethal 
bupivacaine dose with relation to lipid 
concentration. With 30% lipid emulsion, the 
required bupivacaine dose to produce 
asystole was five times higher than with 
saline. Later they showed that after 
bupivacaine-induced cardiac arrest only 
dogs treated with lipid emulsion in addition 
to resuscitation survived when compared to 
saline (Weinberg et al., 2003). 
 In rats, administration of lipid 
emulsion has improved the outcome in 
several settings. The cardiovascular 
outcome has improved after lipid emulsion 
administration both alone (Weinberg et al., 
2008) and when combined with adrenaline 
(Hiller et al., 2009; Li et al., 2012). The 
combination of high adrenaline doses to 
lipid emulsion seemed, however, to impair 
the cardiovascular recovery (Hiller et al., 
2009). Pre-treatment with lipid emulsion has 
also increased the thresholds of both 
convulsions and cardiac arrest (Oda and 
Ikeda, 2013). In resuscitation protocols, 
administration of very high doses of lipid 
emulsion has also affected the distribution 
of bupivacaine by, for example, decreasing 
the cardiac and CNS concentrations while 
increasing the hepatic concentration
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Table 5. Animal studies on lipid rescue in LAST 
Publication Model Local anaesthetic Effect of lipid emulsion 
Weinberg et al., 
1998 part 1 
Rat Bupi 75 mg kg–1 
min–1 until 
cardiac arrest 
Lethal dose was increased after lipid emulsion pre-treatment 
Weinberg et al., 
1998 part 2 
Rat 1. Bupi 15, 17.5, 
20 or 22.5 mg 
kg–1 
2. Bupi 10, 12.5 or 
15 mg kg–1 
Higher survival at similar bupivacaine dose than after saline 
Weinberg et al., 
2008 
Rat Bupi 20 mg kg–1 Higher RPP and arterial oxygen pressure than after adrenaline 
Hiller et al., 
2009 
Rat Bupi 20 mg kg–1 Adrenaline improved initial recovery, but after both lipid 
emulsion alone and combined with 1–2.5 µg kg–1 adrenaline 
the recovery was more sustained 
Li et al., 2012 Rat Bupi 30 mg kg–1 Haemodynamic recovery improved best after lipid emulsion 
and adrenaline, then after lipid emulsion alone. Cardiac 
bupivacaine concentration was lower after lipid emulsion and 
adrenaline. Adrenaline increased hypoxaemia and acidosis. 
Partownavid et 
al., 2012 
Rat Bupi 10 mg kg–1 Inhibition of fatty acid metabolism prevented the resuscitative 
effects of lipid emulsion. 
Oda and Ikeda, 
2013 
Rat 1. Bupi 1 mg kg–1 
min–1 
2. LBupi 1 mg kg–1 
min–1 
Lipid emulsion pre-treatment increased convulsive and cardiac 
arrest threshold 
Shi et al., 2013 Rat Bupi 2 mg kg–1 
min–1 for 4 min 
Bupivacaine concentration decreased in, e.g. brain and 
myocardium, and increased in liver. Bupivacaine half-life 
decreased and clearance increased. 
Fettiplace, 
Ripper, et al., 
2014 
Rat Bupi 10 mg kg–1 Haemodynamic recovery was faster. I.v. administration of lipid 
emulsion was more efficacy than i.o. administration. 
Fettiplace, Akpa, 
et al., 2014 
Rat Bupi 10 mg kg–1 Recovery, e.g. blood pressure, RPP, and carotid flow, was 
faster in relation to lipid concentration. 
Carreiro et al., 
2014 
Rat Coca 10 mg kg–1 Pre-treatment decreased mortality. 
Fettiplace et al., 
2015 
Rat Bupi 10 mg kg–1 Haemodynamic recovery improved, bupivacaine blood 
concentration increased and tissue bupivacaine 
concentrations decreased. 
Weinberg et al., 
2006 
Rat heart Bupi 500 µM Cardiac function recovered faster, bupivacaine concentration in 
heart decreased 
Stehr et al., 2007 Rat heart LBupi 5 mg l–1 Systolic pressure increased 
Zausig et al., 
2009 
Rat heart 1. Bupi 250 µM 
2. Ropi 500 µM 
3. Mepi 1000 µM 
No effect on return of cardiac activity, but improved heart rate 
and RPP in bupivacaine intoxication 
Chen et al., 2010 Rat heart Bupi 100 µM, 
40 µM 3 min after 
asystole 
Recovery was improved, RPP decreased later with higher lipid 
concentration, myocardial bupivacaine concentration 
decreased 
Liu et al., 2012 Rat heart Bupi 100 µM, and 
30 µM 3 min 
after asystole 
Cardiac function recovered faster after lipid emulsion alone and 
combined with adrenaline 
Chen et al., 2014 Rat heart Bupi 40, 60, 80, 
100, 120, 140 or 
160 µM 
Cardiotoxic effects were reversed in relation to bupivacaine 
concentration 
Aumeier et al., 
2014 
Rat heart 1. Bupi 250 µM 
2. Mepi 1000 µM 
Time to asystole increased and recovery expedited in 
bupivacaine intoxication but not in mepivacaine intoxication. 
Ok, Han, et al., 
2013 
Rat aorta 
rings 
1. Bupi 300 µM 
2. Ropi 1000 µM 
3. Lido 3000 µM 
4. Mepi 7000 µM 
Lipofundin better reversed the vasodilation caused by 
bupivacaine compared to Intralipid. Reversal of vasodilation 
caused by other local anaesthetics was similar by both lipid 
emulsions. 
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Lee et al., 2013 Rat aorta 
rings 
1. LBupi 600 µM 
2. Ropi 2000 µM 
3. Mepi 7000 µM 
Enhanced noradrenaline-mediated vasoconstriction. The 
enhancement occurred at lower lipid emulsion concentration 
as the lipid-solubility of local anaesthetic increased. 
Hori et al., 2013 Rat 
microglial 
cells 
1. Bupi 1000 µM 
2. Lido 1000 µM 
Proton currents through voltage-gated proton channels 
improved. 
Wagner et al., 
2014 
Rat cardiac 
myocytes 
1. Bupi 10 µM 
2. Mepi 40 µM 
 
Fast Na+ currents were increased by 37% after lipid emulsion in 
bupivacaine intoxication, and slightly in mepivacaine 
intoxication. 
Cave et al., 2009 Rabbit Bupi 10 mg kg–1 Survival was improved 
Lemoine et al., 
2014 
Rabbit 
Purkinje 
cells 
Bupi 1, 10 or 50 
µM 
Conduction blocks of Purkinje fibres were prevented. 
Weinberg et al., 
2003 
Dog Bupi 10 mg kg–1 Recovery improved, myocardial metabolic function improved 
Mayr et al., 
2008 
Pig Bupi 5 mg kg–1 + 
asphyxia 
Adrenaline and vasopressin improved survival when compared 
to lipid emulsion 
Hicks et al., 
2009 
Pig Bupi 10 mg kg–1 No effect on ROSC, but more noradrenaline was needed after 
lipid emulsion, plasma bupivacaine concentrations were 
higher 
Candela et al., 
2010 
Pig Bupi 4 mg kg–1 Lengthening of intracardiac conduction times was reversed  
Bushey et al., 
2011 
Pig Bupi 5 mg kg–1 No effect on recovery or survival 
Mauch et al., 
2011 
Pig Bupi 1 mg kg–1 
min–1 
Adrenaline improved haemodynamic recovery when compared 
to lipid emulsion 
Mauch et al., 
2012 
Pig Bupi 1 mg kg–1 
min–1 
Survival and haemodynamic recovery was better after 
adrenaline or lipid emulsion combined with adrenaline than 
after lipid emulsion alone 
Litonius et al., 
2012b 
Pig 1. Bupi 2 mg kg–1 
min–1 
2. Mepi 6 mg kg–1 
min–1 
Plasma bupivacaine concentration minimally increased, no 
effect on haemodynamic recovery 
Melo et al., 2012 Pig Bupi 5 mg kg–1 Arterial blood pressure increased trough vasoconstriction 
Bonfim et al., 
2012 
Pig Ropi 7 mg kg–1 Haemodynamic recovery, i.e. blood pressure, cardiac index, 
and peripheral resistance, improved similarly after both LCT 
and MCT lipid emulsions 
(Litonius, 
Lokajová, et 
al., 2012) 
Pig Bupi 2 mg kg–1 
min–1 
No effect on pharmacokinetics or haemodynamic recovery 
when Intralipid compared to POPC/POPG liposomes 
de Queiroz 
Siqueira et al., 
2014 
Pig LBupi 8.3 mg min–
1 
Lipid emulsion alone and combined with adrenaline increased 
achieving ROSC. Adrenaline increased electrocardiogram 
abnormalities. 
Udelsmann and 
Melo, 2015 
Pig Bupi 5 mg kg–1 Haemodynamic recovery improved better after both LCT and 
MCT lipid emulsions. 
Bupi, bupivacaine; Coca, cocaine; Lido, lidocaine; LBupi, levobupivacaine; LCT, long-chain triglycerides; Mepi, 
mepivacaine; MCT, medium-chain triglycerides; POPC/POPG, 1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine/1-
palmitoyl-2-oleyl-sn-glycero-3-(phospho-rac-[1-glycerol]) dispersion; Ropi, ropivacaine; ROSC, return of spontaneous 
circulation; RPP, rate-pressure product. 
 
 
(Fettiplace et al., 2015; Shi et al., 2013). 
These pharmacokinetic findings have not 
always been accompanied by improved 
cardiovascular outcome (Shi et al., 2013) 
even though in some studies, lipid emulsion 
increased blood pressure and carotid flow in 
bupivacaine intoxication (Fettiplace et al., 
2015; Fettiplace, Akpa, et al., 2014). In 
bupivacaine intoxication, the accompanied 
inhibition of the fatty acid β-oxidation also 
prevents the resuscitative effect in rats 
suggesting a metabolic mechanism of action 
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of lipid emulsion in lipid rescue 
(Partownavid et al., 2012). 
 The resuscitative effect of lipid 
emulsion has also been demonstrated in 
isolated rat heart models, as it has expedited 
the recovery of cardiac function and 
decreased bupivacaine concentrations in 
heart (Stehr et al., 2007; Weinberg et al., 
2006). In another rat heart study, lipid 
emulsion improved the recovery from 
bupivacaine intoxication but not from 
ropivacaine or mepivacaine intoxication 
(Zausig et al., 2009). In bupivacaine 
intoxication, lipid emulsion has also 
demonstrated a dose-depended recovery of 
especially heart rate (Chen et al., 2010). On 
the other hand, lipid emulsion has also 
reversed the local anaesthetic -induced 
vasodilation (Ok, Park, et al., 2013) and 
enhanced the vasoconstrictive effect of 
noradrenaline in rat aorta (Lee et al., 2013). 
 In pigs, the efficacy of lipid emulsion 
is more controversial. In some studies, the 
administration of lipid emulsion in clinically 
recommended or higher doses has expedited 
the normalisation of intracardiac conduction 
time prolongation (Candela et al., 2010) or 
improved achieving return of spontaneous 
circulation (de Queiroz Siqueira et al., 
2014). In contrast to rats, adrenaline alone 
or combined with lipid emulsion has proven 
more effective treatment than lipid emulsion 
alone (Hicks et al., 2009; Mauch et al., 
2011; 2012). While the internationally 
recommended dose of lipid emulsion has 
not affected the haemodynamic outcome 
(Litonius et al., 2012b), higher doses, as in 
rat studies, have improved the 
haemodynamic recovery (Bonfim et al., 
2012; Melo et al., 2012; Udelsmann and 
Melo, 2015). 
 
Lipid rescue case reports in local 
anaesthetic systemic toxicity  
Due to shortage of human studies, the 
human experience of lipid emulsion 
treatment in LAST relies mainly on clinical 
case reports. At the moment, there are at 
least 42 such case report publications of 
lipid rescue in systemic toxicities of various 
local anaesthetics. The first of those were 
published in 2006 (Litz et al., 2006; 
Rosenblatt et al., 2006). The possible 
positive publication bias (positive results are 
more likely published than negative), and 
the heterogeneous treatment protocols and 
reporting accuracies between different case 
reports complicate the evaluation of the 
efficacy of lipid rescue. However, according 
to most of the reports, lipid rescue seems to 
be effective. The case reports are 
categorised according to the effect of lipid 
emulsion on the patient’s symptoms in 
Table 6. 
 In most cases, the administration of 
lipid emulsion seemed to abolish the various 
symptoms of LAST varying from mild CNS 
toxicity (Mizutani et al., 2011) to cardiac 
arrest (Scherrer et al., 2013; Sonsino and 
Fischler, 2009). Some authors report a 
dramatic effect which was seen within 
seconds after beginning of lipid rescue 
(Shenoy et al., 2014; Whiteside, 2008). On 
the other hand, some authors report, that 
despite the administration of various 
medications, particularly the lipid emulsion 
administration seemed to be the turn for the 
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Table 6. Case reports on lipid rescue in LAST 
Publication Local anaesthetic Block Symptoms at time of 
lipid emulsion 
administration 
Suggested effect of lipid 
emulsion 
Lipid emulsion had an immediate effect 
Rosenblatt et al., 
2006 
Bupi 1.2 mg kg–1, 
Mepi 3.7 mg 
kg–1 
Interscalene Cardiac arrest Defibrillated to SR after 
lipid emulsion 
Scherrer et al., 
2013 
Ropi 7.9 mg kg–1 TAP Cardiac arrest Cardiac activity 
immediately 
Sonsino and 
Fischler, 2009 
Ropi 150 mg Infraclavicular Cardiac arrest SR immediately 
Cordell et al., 
2010 
Bupi 75 mg Axillary VT SR after lipid bolus 
Shenoy et al., 
2014 
Bupi 2.3 mg kg–1 Caudal VT Sinus tachycardia 
immediately, SR later 
Whiteside, 2008 Bupi 0.29 mg kg–1 Sciatic nerve Seizure Seizures stopped within 
seconds 
Spence, 2007 Lido 0.9 mg kg–1, 
Bupi 0.17 mg 
kg–1 
Epidural Unresponsive Consciousness within 30 s 
Espinet and 
Emmerton, 
2009 
Bupi 1.25 mg kg–
1, Lido 1.25 mg 
kg–1 
Lower leg nerve Mild CNS symptoms, 
ST segment elevation 
Symptoms improved 
within minute 
Charbonneau et 
al., 2009 
Mepi 14.9 mg kg–
1 
Axillary Myoclonus Symptoms disappeared 
immediately 
The effect of lipid emulsion was seen within minutes 
Smith et al., 
2008 
Bupi 1.7 mg kg–1 Sciatic nerve Cardiac arrest SR after 9 min 
Hurley and 
Hanlon, 2009 
Bupi – Cardiac arrest Clinical improvement 
within minutes 
Marwick et al., 
2009 
Bupi 1.6 mg kg–1 Infraclavicular Cardiac arrest Narrow complexes within 
3 min, but periods of 
VT 40 min later. Also 
pancreatitis 
Grenc et al., 
2011 
Lido 20 mg Epidural Cardiac arrest SR within 4 min 
Markowitz and 
Neal, 2009 
Bupi 1.6 mg kg–1 Femoral nerve VF Defibrillated to SR within 
minutes 
Gallagher et al., 
2010 
Bupi 1.9 mg kg–1, 
Lido 10.2 mg 
kg–1 
Subpectorial region PEA Pulse restored during 
second lipid dose 
Dix et al., 2011 Lido blood 
concentration 
7.6 mg l–1 
I.v. infusion PEA SR after 5 min 
Foxall et al., 
2007 
LBupi 1.2 mg kg–
1 
Posterior lumbar 
plexus 
Seizures and CV 
collapse 
BP normalisation after 5 
min 
McCutchen and 
Gerancher, 
2008 
Bupi 150 mg, 
Ropi 150 mg 
Femoral nerve VT Defibrillated to SR some 
minutes after lipid 
emulsion 
Ludot et al., 
2008 
Lido 1.8 mg kg–1, 
Ropi 1.4 mg kg–
1 
Posterior lumbar 
plexus 
VT SR after 2 min 
Fuzaylov et al., 
2010 
Bupi 0.5 mg kg–1 I.v. bolus VT Sinus tachycardia within 2 
min, but hypotension 
persisted 
Arora et al., 2013 Coca Smoking of crack 
coca 
Wide complex 
tachycardia, seizures 
SR within 10 min 
Lin and Aronson, 
2010 
Bupi 1 mg kg–1 Caudal epidural Ventricular complexes SR within 3 min 
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Litz et al., 2008 Mepi 5.3 mg kg–1, 
Prilo 1.75 mg 
kg–1 
Infraclavicular Unresponsive Consciousness after 5 min 
Shah et al., 2009 Bupi 2.0 mg kg–1 Caudal epidural ST segment elevation ECG normalisation within 
minutes 
Bilotta et al., 
2012 
Lido 500 mg, 
Ropi 300 mg 
kg–1 
Subcutaneously in 
head 
Complete 
atrioventricular block 
The block resolved rapidly 
Shih et al., 2011 Bupi 0.8 mg kg–1, 
Lido 4.6 mg kg–
1 
Infraclavicular Junctional bradycardia SR within 2 min 
Wong et al., 
2010 
Bupi 3.1 mg kg–1 
during 8 h 
Epidural Sinus tachycardia and 
hypotension 
BP increased 
Diaz et al., 2012 Bupi 0.5 mg kg–1, 
Lido 4.5 mg kg–
1 
Epidural Unconsciousness, 
hypotension 
Consciousness within 3 
min 
Mizutani et al., 
2011 
Ropi 3.0 mg kg–1 Interscalene Incoherence and other 
mild CNS symptoms 
Symptoms disappeared 
within minutes 
Nguyen and 
White, 2012 
Ropi 1.0 mg kg–1 Supraclavicular Disorientation Symptoms disappeared 
within 2 min 
The effect of lipid emulsion was seen gradually 
Litz et al., 2006 Ropi 8 mg kg–1 Axillary Cardiac arrest ROSC after 10 min 
Whiteman and 
Kushins, 2014 
Bupi 13 mg kg–1 Abdominal 
intramuscular pain 
pump 
Cardiac arrest ROSC within 45 min 
Warren et al., 
2008 
Mepi 5.4 mg kg–1, 
Bupi 0.6 mg kg–
1 
Supraclavicular VF ROSC after 11 min 
Varela and 
Bums, 2010 
Bupi 2.1 mg kg–1, 
Ropi 4.3 mg kg–
1 
Femoral and sciatic 
nerve 
VT SR after a 30-min lipid 
infusion 
Jakkala-Saibaba 
et al., 2011 
Coca Nasal inhalation Seizures and VT periods SR after 15 min 
Harvey et al., 
2011 
Bupi 1.9 mg kg–1, 
Lido 0.6 mg kg–
1 
Femoral nerve Seizures and 
hypotension 
BP normalisation within 
20 min 
Lange et al., 
2012 
Lido 26 mg kg–1 Abdominal 
intramuscular 
injection 
Lowered level of 
consciousness 
Oriented but still lethargic 
after 10 min 
No effect or time scale not reported 
Gnaho et al., 
2009 
Ropi 2.2 mg kg–1 Sciatic nerve VF (worst symptom) No more symptoms at 
time of lipid 
administration 
Kundu et al., 
2013 
Coca – Seizures, wide complex 
arrhythmias 
No effect 
Calenda and 
Dinescu, 2009 
Ropi 1.9 mg kg–1, 
Mepi 5.0 mg 
kg–1 
Axillary Seizures No effect 
Aveline et al., 
2010 
Lido 7 mg kg–1, 
Ropi 2.0 mg kg–
1 
Sciatic nerve Seizures No effect 
Landy et al., 
2012 
Lido 5 mg kg–1 Brachial plexus Seizures Not reported 
Bupi, bupivacaine; BP, blood pressure; Coca, cocaine; CNS, central nervous system; CV, cardiovascular; ECG, 
electrocardiogram; Lido, lidocaine; LBupi, levobupivacaine; Mepi, mepivacaine; Prilo, prilocaine; PEA, pulseless 
electrical activity; Ropi, ropivacaine; ROSC, return of spontaneous circulation; SR, sinus rhythm; TAP, transversus 
abdominis plane; VF, ventricular fibrillation; VT, ventricular tachycardia. 
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better in patient’s condition (Gallagher et 
al., 2010; Litz et al., 2006; Rosenblatt et al., 
2006; Shah et al., 2009; Shih et al., 2011; 
Wong et al., 2010). There are, however, also 
two cases in which lipid emulsion did not 
influence the symptoms of LAST as the 
seizure activity (Aveline et al., 2010; 
Calenda and Dinescu, 2009) and a third in 
which the seizure activity accompanied with 
ventricular arrhythmias continued (Kundu et 
al., 2013) despite lipid rescue. However, the 
two former patients survived without any 
sequelae. 
 Despite convincing case reports, the 
connection of lipid emulsion administration 
to the recovery of the patient can be 
questioned in many cases. In some cases, 
for example, lipid emulsion had been given 
just prior to first defibrillation (Markowitz 
and Neal, 2009), even with other 
medications, such as amiodarone, 
(McCutchen and Gerancher, 2008), and as 
the rhythm successfully converted to sinus 
rhythm, the benefit of lipid emulsion 
remains uncertain. Similarly, some patients 
were administered several medications 
during the cardiopulmonary resuscitation 
and the effect of lipid emulsion cannot with 
certainty be associated with the 
improvement of patient’s clinical status 
(Cordell et al., 2010; Grenc et al., 2011; 
Smith et al., 2008; Warren et al., 2008). 
 Lipid emulsion has been 
administered at the same time with other 
medication, e.g. midazolam, to treat minor 
CNS intoxication (Nguyen and White, 
2012), and also rather mild CNS pretoxicity 
symptoms, such as incoherence, slurred 
speech (Mizutani et al., 2011). Such 
symptoms are typically short-lasting 
(Haasio et al., 1988) and may probably have 
passed rapidly even spontaneously.  
 There are also some alarming 
characteristics that can be noted in some 
case reports. Many anaesthesiologists seem 
to consider lipid emulsion as the first line 
treatment for LAST (Lange et al., 2012; 
Mizutani et al., 2011; Scherrer et al., 2013). 
In one of the most recent case, the authors 
reported no use of other medications than 
lipid emulsion despite that the 
cardiopulmonary resuscitation lasted for 45 
min and required two defibrillations before 
return of spontaneous circulation 
(Whiteman and Kushins, 2014). 
 In addition to modern local 
anaesthetics, lipid emulsion has been used 
to treat cocaine overdoses (Arora et al., 
2013; Jakkala-Saibaba et al., 2011; Kundu 
et al., 2013). The patients were given 
various other medications prior to lipid 
emulsion, but the latter seemed to improve 
the patients’ status markedly in two cases 
(Arora et al., 2013; Jakkala-Saibaba et al., 
2011). On the other hand, in one of the three 
patients lipid emulsion had no effect on the 
wide complex ECG arrhythmias or the 
seizure activity even though the lipid 
treatment was given repeatedly (Kundu et 
al., 2013). In some of the case reports, lipid 
rescue itself seemed to cause complications. 
These events are presented below in a 
separate paragraph ‘Adverse effects’. 
 
Lipid rescue human studies in other drug 
poisonings 
There are currently only two prospective 
human studies of lipid rescue in other drug 
poisonings than those caused by local 
anaesthetics. Minton and colleagues (1987) 
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showed in a randomised cross-over study 
that infusion of 500 ml of 20% lipid 
emulsion during 5 h increased only 
minimally total amitriptyline and 
nortriptyline concentrations after 
amitriptyline administration but there was 
no statistically significant difference 
between lipid emulsion and saline 
treatments. In the other study, lipid 
emulsion treatment showed no clinically 
significant changes in patient population of 
heterogeneous drug poisonings (Taftachi et 
al., 2012). 
 
Lipid rescue animal studies in tricyclic 
antidepressant poisonings 
The use of lipid emulsion in treatment of 
TCA poisoning is much less investigated as 
in treatment of LAST. At the moment, there 
are six controlled animal studies on the 
subject (Table 7). As TCAs are very 
lipophilic, lipid emulsion has entrapped both 
amitriptyline and clomipramine in plasma 
(Harvey et al., 2009; Litonius et al., 2012a; 
Perichon et al., 2013). The haemodynamic 
outcome has, however, varied greatly 
between different studies. In rats and 
rabbits, after administration of amitriptyline 
or clomipramine i.v., lipid emulsion has 
been a superior treatment over both saline 
and sodium bicarbonate (Bania and Chu, 
2006; Harvey and Cave, 2007). Also 
intraperitoneal lipid emulsion dialysis, 
combined with an i.v. therapy, has proven 
beneficial (Harvey et al., 2009). 
 After oral amitriptyline ingestion in 
rats, lipid emulsion has, however, increased 
mortality and retarded recovery (Perichon et 
al., 2013). Similar negative cardiovascular 
effect (Varney et al., 2014) or no effect at 
all (Litonius et al., 2012a) of lipid emulsion 
was seen in pigs after an i.v. administration 
of amitriptyline. 
 
Table 7. Animal studies on lipid rescue in tricyclic antidepressant poisonings 
Publication Model Tricyclic antidepressant Effect of lipid emulsion 
Bania and Chu, 
2006 
Rat Amitriptyline 42 mg kg–1 in 1 h i.v. After lipid emulsion pre-treatment, MAP was 
higher at 45 min 
Perichon et al., 
2013 
Rat Amitriptyline 70 mg kg–1 p.o. Higher mortality, higher amitriptyline plasma 
concentrations, lower BP than after sodium 
bicarbonate treatment 
Harvey and 
Cave, 2007 
part 1 
Rabbit Clomipramine 320 mg kg–1 h–1 i.v. 
until MAP 50% 
MAP recovered faster than after sodium 
bicarbonate 
Harvey and 
Cave, 2007 
part 2 
Rabbit Clomipramine 240 mg kg–1 h–1 i.v. 
until MAP 25 mmHg 
Survival was better than after sodium bicarbonate 
Harvey et al., 
2009 
Rabbit Clomipramine 240 mg h–1 i.v. until 
MAP 50% 
After i.v. and intraperitoneal lipid emulsion 
treatment, MAP recovered faster, higher 
clomipramine concentration in plasma than after 
saline 
Litonius et al., 
2012a 
Pig Amitriptyline 15 mg kg–1 i.v. in 15 
min 
Higher amitriptyline concentration in plasma than 
after Ringer’s acetate, no haemodynamic effect 
Varney et al., 
2014 
Pig Amitriptyline 0.5 mg kg–1 min–1 i.v. 
until MAP 60%, then infusion of 
10% of the initial dose 
Higher mortality, lower BP than after sodium 
bicarbonate treatment 
BP, blood pressure; MAP, mean arterial pressure. 
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Lipid rescue case reports in tricyclic 
antidepressant poisonings 
At the moment, there are at least 17 
different case reports of administration of 
lipid emulsion as a treatment for TCA 
poisoning (Table 8). All patients have been 
treated with several other medications so the 
effect of lipid emulsion may be difficult to 
interpret. The cases can be, however, 
divided to three different groups. In the first, 
the patient’s condition, especially blood 
pressure and cardiac conduction times, 
seemed to improve almost immediately after 
lipid emulsion administration (Agarwala et 
al., 2014; Blaber et al., 2012; Boegevig et 
al., 2011; Engels and Davidow, 2010; 
Harvey and Cave, 2012; Levine, Brooks, et 
al., 2012; Scholten et al., 2012). In some 
other patients, the improvement was seen 
more gradually within an hour or longer 
time (Al-Duaij et al., 2009; Carr et al., 
2009; Eren Cevik et al., 2014). Only one 
patient seemed not to benefit from lipid 
emulsion at all (Kiberd and Minor, 2012). 
 The adverse effects of lipid emulsion, 
reported also in some of these case reports, 
are presented below in a separate paragraph 
‘Adverse effects’. 
 
Adverse effects of lipid emulsions 
There are no studies regarding the potential 
adverse effects of high lipid emulsion doses 
used in lipid rescue. In their original use, 
parenteral nutrition, they are, however, 
considered safe (Waitzberg et al., 2006), but 
also the doses are much lower. Using the 
recommended rescue doses, Litonius and 
colleagues (2012) are the only who have 
controlledly documented the lack of severe 
adverse effects in healthy human volunteers. 
 According to various lipid rescue 
case reports, the administration of high lipid 
emulsion dose may be associated with 
several distinct adverse effects. One of the 
most often reported complication is 
pancreatitis (Bucklin et al., 2013; Levine et 
al., 2014; Levine, Brooks, et al., 2012; 
Levine, Graeme, et al., 2012; Marwick et 
al., 2009; Oakes et al., 2009). Another often 
reported adverse effect is acute respiratory 
distress syndrome (ARDS) (Levine et al., 
2014; Levine, Brooks, et al., 2012; Martin 
et al., 2014). In addition to organ specific 
complications, rapid lipid emulsion 
administration can result in fat overload 
syndrome which include several symptoms, 
e.g., anaemia, leukopenia, 
thrombocytopenia, jaundice, 
hepatosplenomegaly, respiratory distress, 
and spontaneous haemorrhages (Hojsak and 
Kolaček, 2014). 
 In parenteral nutrition, intravenous 
lipid emulsions have been associated with 
both acute hypersensitivity reactions (Lunn 
and Fausnight, 2011; Weidmann et al., 
1997), even anaphylaxis (Ghatak et al., 
2014), and other complications after 
prolonged infusions. These complications 
include, for example, immunologic effects 
by impairing neutrophil function (Versleijen 
et al., 2010), and increasing inflammatory 
markers while decreasing endothelial 
function (Umpierrez et al., 2009). The 
effects on vein endothelium may also cause 
increased risk of vein thrombosis 
(Smirniotis et al., 1999). A case of deep 
venous thrombosis has been recently 
reported also after lipid rescue treatment 
(Schwarz et al., 2014). At least long-term 
infusion of lipid emulsions may also cause
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Table 8. Case reports on lipid rescue in tricyclic antidepressant poisonings 
Publication Tricyclic antidepressant 
p.o. 
Symptoms at time of lipid 
emulsion administration 
Suggested effect of lipid 
emulsion 
Positive effect or possibly positive effect 
Al-Duaij et al., 2009 Imipramine 6 g Unresponsive, hypotensive, 
arrhythmias 
Heart rate stabilised, 
arrhythmias less frequent 
Cooper et al., 2010 Amitriptyline 350 mg and 
several other drugs 
Hypotensive, complete 
heart block 
SR and BP improved 
Boegevig et al., 2011 Dosulepin 5.25 g Wide QRS complex, 
unconscious 
QRS shortened within 15 
min 
Hendron et al., 2011 Dosulepin 45 mg kg–1 Disoriented, VT Sinus tachycardia after 
defibrillation 
Levine, Brooks, et al., 
2012 
Amitriptyline Seizures, wide-complex 
tachycardia 
Seizures ceased, sinus 
tachycardia. Also 
pancreatitis and ARDS 
Levine, Graeme, et al., 
2012 
Doxepin Brady-asystolic arrest Heart rate increased. Also 
pancreatitis 
Blaber et al., 2012 Dosulepin 2.25 g Wide-complex tachycardia SR within minutes 
Scholten et al., 2012 Amitriptyline and other 
drugs 
Wide QRS complex Immediate narrowing of 
QRS 
Perza et al., 2013 Doxepin and other drugs Seizures, hypotensive, wide 
QRS complex 
BP increased, QRS 
narrowed within 2 h, 
seizures continued 
Nair et al., 2013 Amitriptyline 5.6 g, 
citalopram 
GCS 3, VT runs No arrhythmias after lipid 
Bowler and Nethercott, 
2014 
Amitriptyline and 
liraglutide 
Hypotensive, wide QRS 
complex 
QRS normalised and BP 
increased 
Agarwala et al., 2014 Amitriptyline 2.25 g Hypotensive, wide QRS 
complex 
QRS narrowed within 
minutes 
Carr et al., 2009 Doxepin 19 mg kg–1 GCS 3, hypotensive BP stabilisation 2.5 h later 
Engels and Davidow, 
2010 
Amitriptyline 4.25 g Hypotensive Noradrenaline need rapidly 
decreased 
Harvey and Cave, 2012 Amitriptyline 43 mg kg–1 
and several other drugs 
Hypotensive, tachycardic BP begun to normalise 
immediately 
Eren Cevik et al., 2014 
Case 1 
Amitriptyline 925 mg GCS 10, hypotensive GCS 14 and BP increased 
within 1 h 
Eren Cevik et al., 2014 
Case 2 
Amitriptyline 875 mg GCS 7, tachycardic GCS 9, heart rate decreased 
within 1 h 
Eren Cevik et al., 2014 
Case 8 
Amitriptyline 520 mg GCS 12, hypotensive, 
tachycardic 
BP increased, heart rate 
decreased within 1 h 
Eren Cevik et al., 2014 
Case 9 
Amitriptyline Hypotensive, tachycardic BP increased, heart rate 
decreased within 20 min 
Eren Cevik et al., 2014 
Case 10 
Amitriptyline GCS 8 GCS 13 within 1 h 
No effect 
Kiberd and Minor, 2012 Amitriptyline Hypotensive, wide-complex 
tachycardia episodes 
No effect on QRS duration 
nor on BP 
ARDS, acute respiratory distress syndrome; BP, blood pressure; GCS, Glasgow coma scale score; SR, sinus rhythm; VT, 
ventricular tachycardia. 
 
 
several severe liver complications (de 
Meijer et al., 2009; Fallon et al., 2010). 
 In addition to various complications 
directly affecting the patient’s health, the 
lipaemic plasma may interfere with several 
laboratory tests even despite 
ultracentrifugation (Dimeski, 2009; 
Grunbaum et al., 2012; Levine et al., 2014; 
Watt et al., 2009). This interference may 
have indirect deleterious effects on the 
patient’s health, as some other necessary 
treatments may be delayed due to false or 
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unobtainable test results. The lipaemic 
plasma itself may also have serious effects 
as it can obstruct the filters during 
haemofiltration (Jeong, 2014; Rodríguez et 
al., 2014) and complicate extracorporeal 
membrane oxygenation (Lee et al., 2015). 
Similarly, lipid emulsions may interact, and 
even entrap, with other medications used in 
patient’s treatment (Niiya et al., 2010), 
which may affect their efficacy. 
 The present lipid emulsion dose in 
treatment of LAST is based on expert 
opinion: 1.5 ml kg–1 in 1 min followed by an 
infusion of 0.25 ml kg–1 min–1 (Neal et al., 
2010). At the moment, the recommended 
maximum dose varies from 10 ml kg–1 
during the first 30 min (Neal et al., 2012) to 
cumulative dose of 12 ml kg–1 (Cave et al., 
2010). There are, however, no studies 
regarding the maximum safe dose in 
humans. 
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PURPOSE OF THE STUDY 
The purpose of the present study was to learn the incidence of LAST and how widely used its 
treatment with i.v. lipid emulsion is in Finland, and to examine different proposed 
mechanisms of action of i.v. lipid emulsion treatment in drug intoxication. As lipid rescue is 
officially recommended as a treatment for LAST in several countries but its potential 
mechanisms of action remain uncertain, studies on different mechanisms are highly 
warranted. 
 
The specific aims were: 
1. To assess the incidence of serious LAST and how widely lipid rescue is adopted in 
Finnish anaesthesia departments (I). 
2. To evaluate if lipid emulsion can affect also milder cases of LAST: CNS toxicity 
caused by lidocaine and LAST which is accompanied by severe metabolic and 
respiratory acidosis mimicking seizures (II–III). 
3. To investigate if lipid emulsion entraps local anaesthetics lidocaine, levobupivacaine 
and bupivacaine, and the tricyclic antidepressant amitriptyline in plasma and affects 
their pharmacokinetics (II–V) and haemodynamic recovery (III–V). 
4. To examine if lipid emulsion in higher dose than recommended can improve 
cardiovascular recovery by affecting cardiac mitochondrial respiration (V). 
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METHODS 
This thesis consists of five different studies. 
The Study I was made by using a structured 
questionnaire. The Study II is a human 
study with healthy volunteers while the rest 
of the studies (III-V) are animal studies with 
anaesthetised pigs. 
 
QUESTIONNAIRE STUDY (I) 
A structured electronic questionnaire using 
the e-form service provided by the 
University of Helsinki was sent via e-mail 
to anaesthesia department chiefs of all 
public hospitals in Finland in February 
2014. The questionnaire is presented in 
detail in Appendix 1. In total, the 
questionnaire was sent to 5 university 
hospitals (comprising 18 separate university 
hospital-affiliated hospital units), 16 central 
hospitals, 10 district or local hospitals, and 
the Invalid Foundation Orthopaedic 
Hospital (n = 45). The department chiefs’ e-
mail addresses were received from the 
register of the Finnish Society of 
Anaesthesiologists. If the chief did not 
response, two reminders were sent, and 
eventually, any remaining non-respondents 
were contacted by telephone. Later, if LAST 
cases were reported, the department chief 
(and the anaesthesiologists involved, if 
necessary) was contacted again to clarify 
some technical issues (e.g., usage of 
ultrasound guidance and type of regional 
anaesthesia) that preceded the cases. The 
spinal blocks were later excluded from the 
study as the low local anaesthetic dose in 
the procedure is unlike to cause LAST. 
 
HUMAN VOLUNTEER STUDY (II) 
The study protocol was approved by the 
Coordinating Ethics Committee of the 
Helsinki and Uusimaa Hospital District 
(119/13/03/00/2012), and it was conducted 
in the laboratory of Clinical 
Neurophysiology at Meilahti Hospital, 
Helsinki University Central Hospital. Eight 
non-smoking Caucasian male volunteers 
aged 20 to 27 years and with a mean (range) 
body mass index of 24 (20 to 29) kg m–2 
were recruited to the study. All volunteers 
were determined to be healthy according to 
their medical history and routine laboratory 
tests, and none used regular medication. 
 The study protocol is presented in 
Figure 7. The study was conducted using a 
randomised crossover protocol. The 
volunteers were treated with both lipid 
emulsion and placebo in randomised order 
in two sessions which were separated by a 
washout period of at least two weeks. 
 Electroencephalography (EEG) was 
recorded using the Electro-Cap (Electro-Cap 
International Inc., Eaton, OH, USA) 
International 10 to 20-electrode setup (24 
channels, 500 samples s–1) connected to the 
NicOne EEG device (Natus Medical Inc., 
Pleasanton, CA, USA), and with 
simultaneous video monitoring. The 
volunteers were continuously monitored 
using a five-lead ECG, non-invasive blood 
pressure, pulse oximetry sensor attached to 
a finger, and nasal catheter capnography. 
Then, cubital veins in both forearms were 
cannulated using 17 or 16-gauge cannulas: 
one arm for the medication administration, 
and the other for blood sampling. The arm 
into which medications were administered  
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Figure 7. Study II protocol. EEG, electroencephalography. 
 
and the infusion pumps were covered with a 
sheet to blind the subject and EEG analyst.
 After recording baseline values, the 
volunteers were given a 1.5-ml kg–1 i.v. 
bolus of treatment solution (either lipid 
emulsion or Ringer’s acetate) in 1 min. 
Then after a rapid saline flush, they were 
administered 1.0 mg kg–1 of lidocaine i.v. 
followed by another saline flush. After 
lidocaine administration, the same treatment 
solution was infused 0.25 ml kg–1 min–1 for 
30 min. The EEG technician announced the 
time by minute until 10 min after lidocaine 
administration in the otherwise quiet room. 
Five minutes after the lidocaine 
administration, the subjective severity of 
CNS symptoms (numbness mouth/tongue, 
tingling mouth/tongue, metallic taste, 
auditory disturbance, 
dizziness/lightheadedness, incoherence, 
sensation of twitching) was asked for 
separate time-points of 1, 2, 3, 4 and 5 min 
on a three-grade scale: no sensation (0 
points), mild sensation (1 point) or strong 
sensation (2 points). The points were then 
summed separately for each symptom and 
volunteer at each time point. 
 The continuous variables were 
recorded and blood samples collected at 
baseline, and 1, 5, 10, 20 and 30 min after 
the lidocaine administration. A 30-s EEG 
epoch (eyes closed) free of artefacts was 
recorded 60 s before administration of 
lidocaine, and another 120-s EEG epoch 
was recorded starting 20 s after lidocaine 
administration. 
 The chosen lidocaine dose was 
known to be safe, but high enough to 
produce easily recognisable subjective 
toxicity symptoms (Haasio et al., 1988). 
 
ANIMAL STUDIES (III–V) 
After obtaining an approval from the 
National Animal Experiment Board 
(ESAVI-2010-08544/Ym-23, 
ESAVI/4536/04.10.07/2013 and 
ESAVI/5027/04.10.07/2014), all animal 
studies were conducted in the Research and 
Development Unit at Meilahti Hospital, 
8
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Helsinki University Central Hospital, using 
landrace pigs of either sex weighing 20–30 
kg. The estimation of body surface area for 
cardiac measurements in Study V was based 
on the weight (Kelley et al., 1973). Before 
the study, the pigs were fasted over night 
with a free access to water. No 
premedication was used in any of the 
studies. Anaesthesia was induced with 
inhaled 5% isoflurane in 21% oxygen using 
a mask. After the induction, the pigs’ 
tracheas were intubated and they were 
mechanically ventilated with 2% isoflurane 
in 21% oxygen (Servo Ventilator 900C; 
Siemens-Elema, Solna, Sweden). The tidal 
volume of ventilation was adjusted to keep 
the end-tidal carbon dioxide (EtCO2) 
concentration in the range 5.0 to 5.5% at a 
fixed frequency of 20 breaths min–1. 
 Peripheral oxygen saturation (SpO2) 
was monitored via a pulse oximetry sensor 
attached to the tail. A five-lead ECG was 
continuously recorded using surface 
electrodes. 
 A peripheral vein in both ears was 
cannulated for continuous administration of 
i.v. fluids. In Studies III–IV, a catheter 
(Leader Cath 19G; Vygon, Ecouen, France) 
and in Study V a two-lumen central venous 
catheter (7 Fr.; Arrow International, Inc., 
Reading, PA, USA) was inserted into one of 
the internal jugular veins for continuous 
monitoring of central venous pressure 
(CVP). The arterial blood pressure was 
monitored via cannula (Arterial Cannula 
with Flo-Switch 20G; Beckton-Dickinson, 
Singapore) inserted into the femoral artery 
that was exposed by dissection. In Study V, 
a PiCCO® Catheter (5F; Pulsion Medical 
Systems SE, Feldkirchen, Germany) for 
cardiac output and other haemodynamic 
measurements was inserted into the other 
femoral artery, and a lateral thoracotomy 
was performed to expose the wall of the left 
ventricle of the heart. 
 After preparations, the 
haemodynamics was allowed to stabilise for 
approximately 30 min. During this 
stabilisation period the oesophageal 
temperature was adjusted to the range 37.5 
to 39.0°C using warming mattresses and an 
external radiant heater (OPN Ceiling 
Control Unit Type VII; Aragona, Sweden). 
CVP was kept between 2 and 8 mmHg by 
infusing Ringer’s acetate solution (Ringer-
Acetat Baxter Viaflo®; Baxter Medical, 
Kista, Sweden). 
 All continuous variables (i.e., heart 
rate, mean arterial pressure [MAP], SpO2 
and EtCO2) and ECG were recorded with a 
computer connected to a multimodular 
patient monitor (Datex-Ohmeda Division; 
Instrumentarium Corp, Helsinki, Finland), 
and running a data collection software 
(iCentral® and S/5 Collect®; GE Healthcare, 
Helsinki, Finland). These variables were 
later analysed at the same time points that 
blood samples were collected. In Study V, 
systemic arterial pressures, continuous 
cardiac output and systemic vascular 
resistance were monitored and recorded 
using a PiCCO® PulsionFlex® monitor 
(V4.0.0.7 A; Pulsion Medical Systems SE, 
Feldkirchen, Germany). 
 
Study III (levobupivacaine in pigs) 
The study protocol is presented in Figure 8. 
The pigs were paralysed using 4 mg 
pancuronium bromide i.v. (Pancuronium-  
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Figure 8. Study III protocol. FiO2, fraction of inspired oxygen. 
 
Actavis® 2 mg ml–1; Actavis Group PTC 
ehf., Hafnarfjörður, Iceland) 10 min prior to 
the levobupivacaine administration. Then, 
after recording baseline values, 
levobupivacaine (Chirocaine® 7,5 mg ml–1; 
AbbVie Oy, Espoo, Finland) was rapidly 
administered into the internal jugular vein. 
To produce hypercapnia, the minute 
ventilation was immediately reduced by 
30% for 5 min. One minute after the 
levobupivacaine administration, 1 mmol kg–
1 of lactic acid (LD-Lactic acid 90% [T]; 
Sigma-Aldrich Co., St. Louis, MO, USA; 
diluted to 4 mmol ml–1 with isotonic saline) 
was infused into the internal jugular vein to 
produce lactic acidosis. The pigs were then 
randomly treated according to the present 
treatment guidelines in LAST in humans: 
1.5 ml kg–1 in 1 min followed by 0.25 ml 
kg–1 min–1 for 29 min (Cave et al., 2010; 
Neal et al., 2012). After 5 minutes of 
hypoventilation, the minute ventilation was 
returned to the original level and inhaled 
oxygen was raised to 100% for the rest of 
the treatment infusion time. 
 Arterial blood samples were drawn 
and arterial blood gas analyses (ABL800 
FLEX; Radiometer Medical ApS, 
Copenhagen, Denmark) were made from 
blood samples drawn as shown in Figure 8. 
Thirty minutes after the end of the treatment 
infusion, the pigs were euthanised with an 
i.v. bolus of potassium chloride. 
 
Study IV (amitriptyline in pigs) 
The study protocol is presented in Figure 9. 
After recording baseline values, the pigs 
were infused 10 mg kg–1 of amitriptyline 
HCl (Sigma, Darmstadt, Germany) into the 
internal jugular vein at a constant infusion 
rate in 15 min. After a distribution period of 
30 min, the pigs were randomly treated i.v. 
with either lipid emulsion (Intralipid® 20%; 
Fresenius Kabi AB; Uppsala, Sweden) or 
placebo (Ringer’s acetate) as in Study III. 
Both arterial and venous blood samples, and 
tissue samples from the brain via 
craniotomy and the heart via sternotomy 
were taken as shown in Figure 9. After all 
samples had been obtained, the animal was 
euthanised with an i.v. bolus of potassium 
chloride. 
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Study V (bupivacaine in pigs) 
The study protocol is presented in Figure 
10. After obtaining baseline values and 
samples, the pigs were infused bupivacaine 
HCl (Bicain®; Orion Pharma, Espoo, 
Finland) until their MAP decreased to 60% 
of its baseline value. After all measurements 
and samples, inhaled isoflurane was 
discontinued and inspired oxygen was 
raised to 100%. The pigs were then treated 
with a 4-ml kg–1 bolus of either 20% lipid 
emulsion (n = 7) or Ringer’s acetate 
solution (n = 6) in 1 min into the central 
vein in randomised order. Inhaled isoflurane 
was continued at concentration of 1% when 
MAP recovered to 60% of baseline level 
and was raised to 2% when MAP recovered 
to the baseline level. 
 Serial needle biopsies (18G 
Speedcut® biopsy needle; Gallini S.r.l., 
Mantova, Italy) were obtained from the 
heart to assay mitochondrial respiration as 
shown in Figure 10. Similarly, serial arterial 
blood samples, and tissue samples from the 
lungs and the apex of the heart were 
collected for the bupivacaine quantification. 
An experienced cardiac anaesthesiologist, 
blinded to the treatment, recorded epicardial 
 
 
Figure 9. Study IV protocol. 
 
Figure 10. Study V protocol. FiO2, fraction of inspired oxygen. 
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echocardiography from short axis left 
ventricular view during the experiment. The 
left ventricular ejection fraction (EF) was 
measured from M-mode acquisition using 
the Teicholz method (Teichholz et al., 
1976). At the end of study, the pigs were 
euthanised with an i.v. bolus of potassium 
chloride. 
 
BLOOD AND TISSUE SAMPLE HANDLING 
Blood samples 
The blood samples (10 ml each) were drawn 
into heparinised tubes. The plasma was then 
separated from the whole blood by 
centrifugation for 10 min at 2500 g, and 
stored at –22°C. An aliquot of the thawed 
and carefully mixed plasma samples was 
used for quantification of the total plasma 
drug concentrations. 
 Additionally, an aliquot of the plasma 
samples was further centrifuged twice for 10 
min at 14,000 rounds min–1 (20,800 g) in 
order to separate the lipid fraction from the 
aqueous fraction. The un-entrapped drug 
concentration (non-lipid bound) was then 
determined in this aqueous fraction. 
 
Tissue samples 
The tissue samples were rapidly rinsed in 
saline to remove excess blood, and then 
dried on filter paper for 5 s. After drying, 
the samples were wrapped in aluminium foil 
and stored at –22°C. Before drug 
concentration measurements in Study IV, 
approximately 0.5 g of all tissue samples 
were homogenised with an UltraTurrax 
T5FU homogenizer (Janke & Kunkel, 
Staufen, Germany): the brain samples in 4.0 
ml and heart samples in 3.0 ml of water. In 
Study V, the tissue samples (0.3 g) were 
homogenised with an IKA® UltraTurrax 
T25 homogeniser (Janke & Kunkel, 
Staufen, Germany) in 4.0 ml of water. The 
drug concentrations were further determined 
using the methods described below. 
 
Drug concentration quantifications 
The lidocaine concentrations were 
determined using an Agilent 1100 HPLC 
(Agilent Technologies, Waldbronn, 
Germany) coupled to an API 2000 high-
performance liquid chromatography–tandem 
mass spectrometry system (Sciex Division 
of MDS Inc., Toronto, ON, Canada) using 
the method described previously by Bo and 
colleagues (1999). The inter-day 
coefficients of variation were 1.5% and 
3.5% at relevant lidocaine concentrations.  
 The levobupivacaine and bupivacaine 
concentrations were determined using an 
Agilent 1100 HPLC (Agilent Technologies, 
Waldbronn, Germany) coupled to an API 
2000 high-performance liquid 
chromatography–tandem mass spectrometry 
system (Sciex Division of MDS Inc., 
Toronto, ON, Canada) using the method 
described by Hoizey and colleagues (2005). 
The inter-day coefficients of variation were 
6.9%, 4.5% and 5.4% at relevant 
levobupivacaine concentrations. For 
bupivacaine, the in-day coefficients of 
variation were 10% for plasma samples, 
5.4% for heart samples, and 12% for lung 
samples. 
 The amitriptyline concentrations 
were determined using an Agilent 1100 
HPLC (Agilent Technologies, Waldbronn, 
Germany) coupled to an API 2000 high-
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performance liquid chromatography–tandem 
mass spectrometry system (Sciex Division 
of MDS Inc., Toronto, ON, Canada) the 
method described by Samanidou and 
colleagues (2007). The coefficients of 
variation for plasma samples were 3.7%, 
3.1% and 3.5%, and for tissue samples 
5.4%, 4.6% and 2.0% at relevant 
amitriptyline concentrations.  
 
Mitochondrial respiration assay 
The mitochondrial respiration was assayed 
using the Oxygraph-2k (OROBOROS 
Instruments Corp., Innsbruck, Austria). The 
heart biopsies (mean weight 3.7 mg) were 
immediately transferred to ice-cold relaxing 
solution BIOPS (50 mM K+-MES, 20 mM 
taurine, 0.5 mM dithiothreitol, 6.56 mM 
MgCl2, 5.77 mM ATP, 15 mM 
phosphocreatine, 20 mM imidazole, pH 7.1, 
adjusted with 5 N KOH at 0 °C, 10 mM Ca–
EGTA buffer [2.77 mM CaK2–EGTA + 
7.23 mM K2–EGTA; 0.1 mM free calcium]) 
for the transportation (Pesta and Gnaiger, 
2011). Before the assays, the heart biopsies 
were transferred into shredder tubes 
containing 500 µl of MiR06 respiration 
buffer (0.5 mM ethylene glycol tetraacetic 
acid, 3mM MgCl2·6 H2O, 60 mM K-
lactobionate, 20 mM taurine, 10 mM 
KH2PO4, 20 mM 4-[2-hydroxyethyl]-1-
piperazineethanesulfonic acid, 110 mM 
sucrose, 1 g l–1 BSA, and 280 u ml–1 
catalase) (Fasching et al., 2014), and 
shredded using a SHREDDER SG3 
(Pressure BioSciences Inc., South Easton, 
MA, USA). The shedder tube was then 
flushed with 2000 µl of MiR06, and a total 
of 2500 µl of the homogenate was 
transferred into one of the two Oxygraph-2k 
chambers for analysis. The biopsies taken at 
0 and 10 min time points were analysed 
simultaneously and the baseline sample in a 
second round approximately 1 h later. 
 The oxygen flux per mass was 
measured during a fatty acid substrate-
uncoupler-inhibitor titration protocol 
(Lemieux et al., 2011; Pesta and Gnaiger, 
2011). The substrates were added in the 
following order: malate (0.8 M, 5 µl) and 
palmitoyl-L-carnitine (10 mM, 4 µl), 
adenosine diphosphate (ADP; 0.5 M, 5 µl) 
and MgCl2 (0.6 M, 5 µl), glutamate (2 M, 
10 µl), succinate (1 M, 20 µl), uncoupler 
carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP; 
1 mM) in three steps of 1 µl, and rotenone 
(0.2 mM, 2 µl). Oxygen flux was 
determined after every substrate. 
 
STATISTICAL ANALYSES 
The statistical analyses were performed 
using Prism 6.0b–g for Mac OS X 
(GraphPad Software, Inc., La Jolla, CA, 
USA). 
 The incidence rates of LAST were 
calculated using the fraction of total analysis 
and the Clopper-Pearson method to 
calculate 95% confidence intervals, and 
compared using Fisher’s exact test (I). 
Variables are presented as mean and 
standard deviation (SD), median and 
interquartile range (IQR), and fractions of 
total with 95% confidence intervals. The 
differences between treatments were 
analysed using paired t-test (II–V), unpaired 
t-test (III–V), Mann-Whitney U test (III–
IV), or Wilcoxon matched pairs test (II). 
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The Holm-Bonferroni method (Holm, 1979) 
was used to adjust P-value for multiple 
comparisons (II–III). The effect of treatment 
over time in Study V was tested using two-
way analysis of variance with repeated 
measures with values of the haemodynamic 
variable over time as within factors, the 
treatment as the between factor, and their 
interactions over time. Also Sidak post 
testing was used. The mitochondrial oxygen 
flux was analysed using unpaired t-test (V).  
 The drug pharmacokinetics was 
analysed by calculating the area under the 
concentration-time curve from 0 to 10, 30 or 
60 min (AUC0–10 min, AUC0–30 min, or AUC0–
60 min, respectively) and the estimation of its 
context-sensitive t1/2. The AUC of drug was 
calculated using the linear trapezoidal rule 
while the t1/2 of the drug was determined 
using non-linear regression. 
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RESULTS 
QUESTIONNAIRE STUDY 
A reply was received from all 45 
departments, i.e. the response rate was 
100%. The total number of regional 
anaesthetic procedures performed by 
anaesthesiologists in those departments was 
approximately 436,300 during the years 
2011–2013. After excluding spinal 
anaesthesias, the total number of regional 
anaesthesias was approximately 211,700 in 
the question departments in Finland. 
 In total, 15 LAST cases were 
reported for the study period: 4 in university 
hospitals, 11 in central hospitals and 0 in 
regional hospitals. When proportioned to the 
large-dose procedures (spinal blocks 
excluded), the total incidence (95% 
confidence interval) of LAST was 0.7 (0.4–
1.2) per 10,000 regional anaesthesias, and 
0.3 (0.09–0.9) per 10,000 regional 
anaesthesias in the university hospitals, 1.4 
(0.7–2.5) per 10,000 regional anaesthesias 
in the central hospitals, and 0 (0–2.1) per 
10,000 regional anaesthesias in the regional 
hospitals. The risk for LAST was higher in 
the central hospitals than in the university 
hospitals (relative risk [RR] 4.0 [95% 
confidence interval, 1.3–12; P = 0.02]). A 
similar increased risk was seen when all 
non-university hospitals (regional hospitals 
included) were compared to the university 
hospitals (RR 3.3 [95% confidence interval, 
1.0–10.3; P = 0.04]). No deaths due to 
LAST were reported. 
 Only one case of cardiotoxicity 
following regional anaesthesia was reported. 
This paediatric patient was the only one of 
the LAST cases during the years 2011–2013 
reported to the Register for Adverse Drug 
Reactions of Finnish Medicines Agency. 
The patient had developed ventricular 
tachycardia following a sacral block 
(bupivacaine with adrenaline) and lipid 
emulsion had been administered but only 
after the normalisation of rhythm. The other 
14 reported cases were limited to CNS 
symptoms (seizures). Nine of them 
underwent interscalene brachial plexus 
block, two axillary brachial plexus block, 
two intercostal nerve block and one 
infraclavicular brachial plexus block. Four 
of the patients had been treated with lipid 
emulsion, but only after passing of the acute 
symptoms. In university hospitals, the 
anaesthesiologist had used ultrasound 
guidance in 1 of the 4 cases, and in central 
hospitals, in 4 of the 11 cases.  
 In 22 (49%) departments, there was a 
protocol for the treatment of LAST and lipid 
emulsion infusion was included in 21 (47% 
of all departments) of these protocols. In 
seven (33% of departments with lipid rescue 
protocol) hospitals, the lipid emulsion was 
stored in the resuscitation trolley for 
immediate use. 
 The internationally recommended 
commercial lipid emulsion Intralipid® 20% 
is used in 17 hospitals, three hospitals used 
ClinOleic® 20%, and one hospital used 
SMOFlipid® 20%. Six hospitals use the 
protocol from the Lipidrescue.org website, 
six the protocol published by ASRA (Neal 
et al., 2012), one hospital used the protocol 
published by AAGBI (Cave et al., 2010), 
and six used a protocol of their own 
devising. 
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PLASMA DRUG CONCENTRATIONS 
Study II (human study) 
Lidocaine plasma concentrations are shown 
in Figure 11. The mean (SD) peak plasma 
lidocaine concentrations (Cmax) were 0.88 
(0.21) mg l–1 during lipid emulsion and 1.04 
(0.29) mg l–1 during Ringer’s acetate 
administration (P = 0.10), and the median 
(range) time to Cmax was 5 (1–5) min during 
both treatments. From 5 min on, the 
lidocaine concentration decreases with a 
mean (SD) context-sensitive plasma t1/2 of 
32 (28) min during lipid emulsion and 30 
(19) min during Ringer’s acetate (P = 0.61). 
 The mean (SD) AUC0–30 min of plasma 
total lidocaine was 17.4 (4.0) mg min l–1 
during lipid emulsion infusion and 21.3 
(5.2) mg min l–1 during Ringer’s acetate 
infusion (P = 0.10). The mean (SD) AUC0–
30 min of un-entrapped lidocaine (16.4 [3.4] 
mg min l–1) was slightly smaller (5.9%) than 
that of total lidocaine during lipid emulsion 
infusion (P = 0.019) and clearly smaller 
(23%) than that of lidocaine during Ringer’s 
acetate infusion (P = 0.044).  
 
Study III (levobupivacaine in pigs) 
Immediately after its injection, the mean 
(SD) Cmax of levobupivacaine was 35.3 (4.6) 
mg l–1 in the Lipid group and 36.3 (11.7) mg 
l–1 in the Ringer group (P = 0.81), from 
which it decreased rapidly during next 
minutes (Figure 12). From time point 5 min 
on, the total plasma concentration of 
levobupivacaine decreased with a mean 
(SD) context-sensitive plasma t1/2 of 52.2 
(10.8) min in the Lipid group, and 57.4 (9.4) 
min in the Ringer group (P = 0.30). 
 
Figure 11. Mean plasma lidocaine 
concentrations in eight healthy volunteers 
after 1 mg kg–1 lidocaine i.v. The area under 
the concentration-time curve from 0 to 30 
min of un-entrapped lidocaine was smaller 
than that of total lidocaine in the Lipid 
phase (P = 0.019) and that of total 
lidocaine in the Ringer phase (P = 0.044). 
Error bars show standard deviation. 
 
 
 The mean (SD) AUC0–60 min of 
plasma total levobupivacaine concentration 
was 384.4 (92.6) mg min l–1 in the Lipid 
group, and 346.5 (59.7) mg min l–1 in the 
Ringer group (P = 0.32). The mean (SD) 
AUC0–60 min of un-entrapped 
levobupivacaine plasma concentration was 
383.0 (95.0) mg min l–1, and did not differ 
from that of plasma total levobupivacaine in 
the Lipid group (P = 0.67). 
 
Study IV (amitriptyline in pigs) 
In Study IV, both arterial and venous 
amitriptyline concentration decreased by 
75–80% indicating distribution of the drug 
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Figure 12. Mean plasma levobupivacaine 
concentrations in 10 anaesthetised pigs per 
group after 3 mg kg–1 of levobupivacaine 
(L) i.v. There were no differences in the 
areas under the concentration-time curve 
from 0 to 60 min between the treatments. 
Error bars show standard deviation. 
 
 
into tissues (Figure 13). During the lipid 
emulsion treatment, the arterial plasma 
amitriptyline concentration remained rather 
stable while in the Ringer group it decreased 
with a mean (SD) context-sensitive plasma 
t1/2 of 46 (8) min. The total amitriptyline 
concentration was higher in the Lipid group 
from 20 min after start of treatment (i.e. 50-
min time point) on. The un-entrapped 
amitriptyline concentrations were lower 
than the total concentrations after the 
beginning of the lipid emulsion infusion.  
 The venous amitriptyline 
concentration decreased after the start of 
lipid emulsion infusion, but in an irregular 
fashion, which prevented a reliable 
calculation of context-sensitive plasma half-
life. In the Ringer group, the concentration 
decreased with a mean (SD) t1/2 of 58 (11) 
min, and there were no differences in the 
amitriptyline concentrations between 
groups. The un-entrapped venous 
amitriptyline concentrations were, however, 
lower than the total concentrations from the 
beginning of lipid emulsion infusion. 
 
 
Figure 13. Mean arterial and venous plasma amitriptyline concentrations in 10 anaesthetised 
pigs per group after 10 mg kg–1 of amitriptyline i.v. Error bars show standard deviation. *P 
<0.05 between total concentrations in the Lipid and Ringer groups. #P <0.05 between total 
and un-entrapped concentrations in the Lipid group. 
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Study V (bupivacaine in pigs) 
Immediately after bupivacaine infusion, its 
mean (SD) Cmax was 21.5 (2.5) mg l–1 in the 
Lipid group and 19.5 (2.9) mg l–1 in the 
Ringer group (P = 0.21; Figure 14). In the 
Lipid group, the mean (SD) AUC0–10 min of 
plasma total bupivacaine concentration was 
105.2 (13.6) mg min l–1, and 88.1 (7.1) mg 
min l–1 in the Ringer group (P = 0.019). The 
mean (SD) AUC0–10 min of un-entrapped 
bupivacaine, 97.0 (14.5) mg min l–1, was 
smaller than that of total concentration in 
the Lipid group (P <0.0001), but did not 
differ from that of the total concentration in 
Ringer group (P = 0.20). 
 
 
 
Figure 14. Mean plasma bupivacaine 
concentrations in six (Ringer group) and 
seven (Lipid group) anaesthetised pigs after 
bupivacaine infusion. The area under the 
concentration-time curve from 0 to 10 min 
of total bupivacaine was smaller in the 
Ringer group (P = 0.019). The area under 
the concentration-time curve from 0 to 10 
min of un-entrapped bupivacaine was 
smaller than that of total bupivacaine in the 
Lipid group (P <0.0001). Error bars show 
standard deviation. L, lipid emulsion bolus; 
R, Ringer’s acetate bolus. 
 
TISSUE DRUG CONCENTRATIONS 
Study IV (amitriptyline in pigs) 
In Study I, the mean (SD) brain 
amitriptyline concentration was lower 15 
min after the end of lipid emulsion infusion 
(11.5 [2.8] mg kg–1) than after Ringer 
infusion (15.3 [4.5] mg kg–1) (Figure 15; P 
= 0.038). In the heart, the corresponding 
concentrations were 5.1 (1.4) mg kg–1 in the 
Lipid group and 6.1 (1.2) mg kg–1 in the 
Ringer group (P = 0.086). 
 
Study V (bupivacaine in pigs) 
In Study V, the mean (SD) bupivacaine 
concentration in the heart was 10.2 (6.2) mg 
kg–1 in the Lipid group and 12.0 (4.6) mg 
kg–1 in the Ringer group (P = 0.56). The 
 
Figure 15. Mean brain and heart 
amitriptyline concentrations in in six 
(Ringer group) and seven (Lipid group) 
anaesthetised pigs 10 min after bupivacaine 
infusion. Error bars show standard 
deviation. *P <0.05. 
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corresponding lung concentrations were 
22.5 (3.0) mg kg–1 and 19.7 (7.2) mg kg–1, 
respectively (P = 0.38). 
 
HAEMODYNAMICS AND ECG 
Study II (human study) 
MAP, heart rate and respiratory rate all 
increased slightly after lidocaine 
administration (data not shown). Mean heart 
rate, which increased the most, returned to 
near baseline value within 5 min. Peripheral 
oxygen saturation remained unchanged 
during both treatments. There were no 
differences between treatments.  
 
Study III (levobupivacaine in pigs) 
One pig in both groups died in the 
beginning of rescue treatment in spite of 
cardiopulmonary resuscitation and 
adrenaline administration. The mean MAP 
remained stable after the levobupivacaine 
and lactic acid infusion even though four 
pigs (two in each group) developed severe 
hypotension (in addition to those two pigs 
that died). Three of those four pigs (two in 
the Lipid group and one in the Ringer 
group) were given adrenaline i.v. as MAP 
decreased below the predetermined value of 
25 mmHg. To eliminate the effect of 
adrenaline, those pigs were excluded from 
haemodynamic analyses at next two time 
points. The arterial blood pressure increased 
similarly in both groups after the beginning 
of treatment. The mean (SD) peak MAP was 
93 (16) mmHg in the Lipid group and 82 
(26) mmHg in the Ringer group (P = 0.34). 
There were also no differences at any later 
time point. 
 After the levobupivacaine infusion, 
the mean heart rate decreased slightly in 
both groups but began to increase during the 
lactic acid infusion. The time course of heart 
rate followed that of MAP returning to near 
baseline level within 10 min in both groups 
without differences between the groups.  
 By the end of hypoventilation period, 
peripheral oxygen saturation had decreased 
below 75% in both groups, after which it 
normalised rapidly. There were no 
differences in peripheral oxygen saturation 
between the groups. 
 The cardiac conduction times, 
especially QRS duration, prolonged equally 
in both groups during the intoxication 
phase. The median (IQR) time to 
normalisation of QRS width to baseline was 
245 s (198–477 s) in the Lipid group, and 
245 s (165–382 s) in the Ringer group (P = 
0.59). 
 
Study IV (amitriptyline in pigs) 
In Study I, the MAP decreased by 20–30% 
during the amitriptyline infusion and 
returned almost to the level before 
amitriptyline within 30 min. Because the 
MAP and heart rate were slightly, but 
significantly higher in the Lipid than Ringer 
group already at the start of treatment 
infusions, later values were compared with 
the 30-min time point values. With the 
exception of a transient small increase in the 
Lipid group 5 min after the star of 
treatment, there were no differences 
between the groups in the change of MAP 
(Figure 16). Two pigs became bradycardic 
and developed severe hypotension during 
lipid emulsion infusion, and were given 
adrenaline to prevent cardiac arrest. Their  
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Figure 16. Median change of mean arterial 
pressure after the start of rescue infusions. 
Error bars show 25th to 75th percentile. *P 
<0.05 between groups. 
 
MAP was considered 25 mmHg from the 
administration of adrenaline on. Excluding 
these two pigs, heart rate remained 
unchanged in both groups after the start of 
treatment. 
 ECG showed an equal prolongation 
of intracardiac conduction times (PQ and 
QRS duration; data not shown) after 
amitriptyline infusion. There were no 
differences in PQ, QRS or QTc times 
between the groups at any time points. 
 
Study V (bupivacaine in pigs) 
Two pigs in the Lipid group and one pig in 
the Ringer group developed cardiac arrest 
after bupivacaine infusion and were given 
cardiac massage until the end of experiment. 
These pigs were excluded from the 
haemodynamic analyses. During the 
echocardiography measurements and 
cardiac needle biopsy, immediately after 
bupivacaine infusion, MAP continued to 
decrease to a mean of 44% of its baseline 
level until the treatment boluses were given. 
The treatment-time interaction of MAP was 
significant (P <0.0001; Figure 17A). Sidak 
post hoc testing revealed a significantly 
higher MAP in the Lipid group at time 
points 2 to 5 min when compared to the 
Ringer group (P <0.05). 
 
Similar to arterial blood pressure, the 
treatment-time interaction of systemic 
vascular resistance index (SVRI) was 
significant (P <0.0001; Figure 17B). Sidak 
post hoc testing revealed significantly 
higher SVRI in the Lipid group at time 
points 3 to 5 min when compared to the 
Ringer group (P <0.05). 
 After bupivacaine infusion, cardiac 
index decreased similarly in both groups 
and remained reduced throughout the 
experiment (Figure 18A). The treatment-
time interaction was significant (P = 
0.0035), but in Sidak post hoc testing there 
were no differences between the groups at 
any time points. Also left ventricular EF 
decreased after bupivacaine but began to 
increase similarly after treatment boluses in 
both groups, and the treatment-time 
interaction was not statistically significant 
(P = 0.49; Figure 18B). 
 
ARTERIAL BLOOD GASES 
During the hypoventilation phase and i.v. 
infusion of lactic acid in Study III, all pigs 
developed hypoxaemia (decreased 
peripheral oxygen saturation) and 
hypercapnia. At the end of lactic acid 
infusion, the blood gas analyses showed 
severe respiratory and metabolic acidosis 
(mean pH 7.07 in the Lipid group and pH 
7.08 in the Ringer group). There were no 
differences in arterial blood gas analyses at 
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Figure 17. A. Time course of mean arterial pressure differed significantly between groups, P 
<0.0001. B. The time course of mean systemic vascular resistance index differed significantly 
between groups, P <0.0001. Error bars show standard deviation. In Sidak post-testing ***P 
<0.001, **P <0.01, *P <0.05 between the groups. L, lipid emulsion bolus; R, Ringer’s 
solution bolus. 
 
 
Figure 18. A. The time course of mean cardiac index differed between groups P = 0.0035. In 
Sidak post-testing there was, however, no difference between the groups at any time point. B. 
Mean left ventricular ejection fraction. Error bars show standard deviation. L, lipid emulsion 
bolus; R, Ringer’s solution bolus. 
 
baseline or 0 min time point. Within 
minutes after the end of lactic acid infusion, 
the acid-base balance began to normalise 
(Table 9). The normalisation of pH was 
faster in the Ringer group than in the Lipid 
group. After statistical correction for 
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Table 9 Arterial blood gas analyses in Study III 
 Lipid Ringer P value 
3 min 
pH 7.27 (0.07) 7.36 (0.07) 0.005* 
PaO2 (kPa) 6.4 (1.0) 10.3 (8.8) 0.17 
PaCO2 (kPa) 7.3 (0.6) 6.1 (1.4) 0.02 
Lactate (mmol l–1) 5.1 (1.4) 3.7 (1.1) 0.02 
Base excess (mmol l–1) –2.9 (4.9) –0.3 (2.2) 0.14 
5 min 
pH 7.35 (0.06) 7.42 (0.04)  0.005* 
PaO2 (kPa) 49.5 (10.4) 47.0 (17.0)  0.70 
PaCO2 (kPa) 6.1 (0.8) 5.3 (0.7)  0.03 
Lactate (mmol l–1) 4.5 (1.1) 3.7 (1.4)  0.19 
Base excess (mmol l–1) –0.7 (2.7) 1.0 (2.6) 0.19 
Values are means (standard deviations). *P value significant after Holm-Sidak correction. PaCO2, arterial carbon dioxide 
pressure; PaO2, arterial oxygen pressure. Modified from Study III. 
 
 
multiple comparisons, BE, lactate or PaCO2 
did not, however, differ at any time point. 
MITOCHONDRIAL RESPIROMETRY 
In Study V, the analysis of mitochondrial 
respiration revealed a significantly higher 
oxygen flux after the following substrates in 
the Lipid group than in Ringer group: 
glutamate, succinate, FCCP, and rotenone 
(Figure 19). There were no differences 
between the mitochondrial oxygen flux at 
end of bupivacaine infusion and that at 
baseline at any step of the respirometry 
protocol. 
 
CENTRAL NERVOUS SYSTEM TOXICITY 
Electroencephalography 
In Study II, EEG spectral power at baseline 
was comparable between study phases. The 
power in delta, alpha and beta bands 
increased similarly after lidocaine during 
both treatments. The median percentual 
changes in the delta power band, which was 
most affected, ranged from 37% to 72% 
during lipid emulsion, and from 15% to 
54% during Ringer’s acetate without 
Figure 19. Mean cardiac mitochondrial 
respiration of the pigs was stimulated after 
lipid emulsion administration when 
compared to Ringer’s solution (*P <0.05) 
through complex I after glutamate (Glu), 
through complex I and II after succinate 
(Suc), and after uncoupling, through 
complex I and II (FCCP) and complex II 
alone after rotenone (Rot). Error bars show 
standard deviation. M, malate; Pal, 
palmitoyl-L-carnitine; ADP, adenosine 
diphosphate; FCCP, carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone. 
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differences between the study phases. Theta 
power band remained unaffected. Based on 
visual evaluation, there were no 
epileptiformic disturbances present in any of 
the EEG recordings. 
 
Subjective symptoms 
During both phases of Study II, all 
volunteers reported clear symptoms of 
lidocaine CNS toxicity. The toxicity 
symptoms (numbness mouth/tongue, 
tingling mouth/tongue, metallic taste, 
auditory disturbance, 
dizziness/lightheadedness, incoherence, 
sensation of twitching) began within a 
minute after lidocaine administration. After 
summing the symptoms for each volunteer, 
there were no difference between 
treatments: P = 0.98 at 1 min, P = 0.88 at 2 
min, P = 0.75 at 3 min, P = 0.81 at 4 min, 
and P = 0.50 at 5 min. Almost all sensations 
of CNS toxicity resolved within 5 min. 
Seven volunteers during lipid emulsion and 
six volunteers during Ringer’s solution had 
visible fasciculations in the eyelids or 
extremities ending within two minutes after 
lidocaine administration. No other objective 
signs of CNS toxicity were noted. 
 
ADVERSE EFFECTS 
In Study II, four of the eight volunteers 
reported pain in the arm into which lipid 
emulsion had been administered, and it 
lasted for approximately 30 min. There was 
no pain during the Ringer phase of the 
study. 
 Four pigs in Study III developed mild 
redness of the skin during lipid emulsion 
infusion. Similar redness was seen also in 
three pigs in Study IV, and in three pigs in 
Study V. The redness was not accompanied 
with particular haemodynamic instability or 
with changes in airway pressures. 
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DISCUSSION 
MAIN FINDINGS 
The incidence of LAST in Finland was very 
low (I). With only 15 cases of LAST during 
the years 2011–2013, the total incidence 
was 0.7 per 10,000 regional anaesthesias 
(excluding spinal blocks). After dividing the 
hospitals by their level, the incidence 
proved to be four times higher in the central 
hospitals than in university hospitals. LAST 
was most rare in regional hospitals but the 
total number of regional anaesthesias was 
also much lower in those hospitals. Even 
though the efficacy and mechanisms of 
action of lipid rescue remain uncertain, lipid 
emulsion has been adopted as a part of 
treatment of LAST in 47% of Finnish 
anaesthesia departments. 
 The ability of lipid emulsion to 
entrap drugs in the plasma is drug and dose 
dependent. The most lipophilic drug 
studied, amitriptyline (approximately 20 
times more lipophilic than bupivacaine or 
levobupivacaine), was both entrapped to 
arterial plasma and drawn away from 
critical tissues, especially from brain (IV). 
Local anaesthetics, such as lidocaine and 
levobupivacaine (II–III), seem not to be 
lipophilic enough to be entrapped by lipid 
emulsion used in clinically recommended 
doses (Cave et al., 2010; Neal et al., 2012). 
However, when the lipid emulsion dose was 
increased, bupivacaine was entrapped into 
plasma (V). Lipid emulsion affected the 
lidocaine pharmacokinetics by increasing Vd 
in healthy volunteers (II). 
 The CNS toxicity symptoms of 
lidocaine could not be prevented or 
alleviated by using lipid emulsion (II). EEG 
revealed an increased power especially in 
the delta band as a mark of disturbance of 
cortical function (Smith, 2005) after 
lidocaine administration without differences 
between lipid emulsion and placebo 
treatment. Also the severity or duration of 
subjective symptoms did not differ between 
rescue treatments. 
 Complex I and II mediated cardiac 
mitochondrial respiration was stimulated by 
administration of lipid emulsion (V). This 
stimulated function was not, however, 
accompanied by improved cardiac function 
as measured as cardiac index or left 
ventricular ejection fraction. Improved 
haemodynamic recovery could be 
demonstrated only in Study V using a large 
lipid emulsion dose. This improved 
recovery was associated with increased 
peripheral vascular resistance and a rise of 
arterial blood pressure after lipid emulsion. 
In Study III, there were no differences in 
haemodynamic recovery, and in Study IV, 
the haemodynamics were near normal by 
the start of treatment infusions. 
 
THE EXPERIMENTAL MODEL COMPARED 
TO A CLINICAL SITUATION 
A typical case of LAST occurs after 
unintentional intravascular injection of the 
drug (Ecoffey et al., 2014). The more 
uncommon cause of LAST is absorption of 
the drug from tissues after a substantial dose 
(Whiteman and Kushins, 2014). The clinical 
presentation of LAST in published cases has 
ranged from mild CNS toxicity (Espinet and 
Emmerton, 2009; Mizutani et al., 2011) to 
seizures (Calenda and Dinescu, 2009; 
Whiteside, 2008) and to cardiotoxicity 
unresponsive to treatment (Litz et al., 2006; 
Rosenblatt et al., 2006). Seizures, that 
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typically precede cardiac symptoms, can 
rapidly render the patient hypoxic and 
acidotic (Dernedde et al., 2004; Rosenberg 
et al., 1983; Tuominen et al., 1991). 
Acidosis ionises the basic local anaesthetic 
molecules and increases both the amount of 
protein-unbound drug concentration (Coyle 
and Park, 1985) and the intracellular 
binding of local anaesthetics to sodium 
channels (Scott, 1986), which worsens the 
systemic toxicity (Heavner et al., 1992; 
Porter et al., 2000; Rosen et al., 1985). To 
mimic less severe symptoms of LAST after 
rapid i.v. injection of local anaesthetic, a 
bolus dosing was used in Studies II and III. 
In Study III, the infusion of lactic acid after 
local anaesthetic injection simulated those 
aforementioned typical pathophysiological 
changes caused by seizures. In Study V, the 
infusion of bupivacaine until MAP 
decreased to 60% of its baseline level 
resembled more a case of substantial rapid 
absorption of bupivacaine from tissues. The 
MAP decrease to 60% was chosen because 
in pilot studies, MAP continued to decrease 
during the echocardiography measurements 
and mitochondrial biopsy sampling until 
treatment began and lower target MAP 
would probably have lead to cardiac arrest. 
Even with current doses in Studies III and 
V, some pigs developed cardiac arrest and 
could not be resuscitated.  
 In clinical cases of amitriptyline 
poisoning the drug is taken orally after 
which it absorbs gradually from the 
gastrointestinal tract. Often part of the 
ingested drug is still unabsorbed at the time 
of hospital admission and activated charcoal 
can be used to prevent the further 
absorption. In the experimental model of 
Study IV, amitriptyline was, however, given 
i.v. as an infusion to standardise the drug 
dose and to avoid the inter-individual 
differences in gastrointestinal absorption. 
To mimic a clinical situation in which part 
of the drug has already been absorbed, its 
further absorption is prevented, and the 
absorbed drug has mainly distributed into 
vital organs, such as brain and heart, 
amitriptyline was let to distribute for 30 min 
after the infusion. The plasma 
concentrations after the infusion of 10 mg 
kg–1 amitriptyline in our pigs were 
comparable to clinical situations of 
amitriptyline poisonings in humans (Hultén 
et al., 1991). The brain and heart 
amitriptyline concentrations in our pigs 
were also comparable to the post-mortem 
tissue concentrations after fatal amitriptyline 
poisonings in humans (Bynum et al., 2005; 
Musshoff et al., 2004; Tracqui et al., 1990). 
 Since it is unethical to give toxic drug 
doses to humans, animal models were 
adopted to mimic clinical intoxications in 
humans. To minimise the inter-species 
differences, all animal studies were 
conducted using pigs which closely 
resemble humans (see ‘Limitations’ below, 
page 62). 
 
LIPID EMULSIONS 
The fatty acids in the lipid emulsion can be 
divided into short (up to 4 atoms in the 
carbon chain), medium (6 to 12 carbon 
atoms) and long (over 12 carbon atoms). 
The lipid emulsion used in Studies II–V was 
Intralipid® which consists of long-chain 
triglycerides derived from soya bean oil. 
The triglyceride composition can, however, 
vary greatly between different lipid 
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emulsions as they can be derived from, for 
instance, olive, coconut or fish oils 
(Carpentier and Dupont, 2000). Another 
clinically widely used lipid emulsion, 
ClinOleic®, is mainly composed of olive oil 
based triglycerides and to a lesser degree of 
soya bean oil based (Calder et al., 2010) 
while the triglycerides of another clinical 
lipid product SMOFLipid® are coconut, 
soya bean, olive and fish oil derived (Calder 
et al., 2010). Therefore, the main 
triglyceride in Intralipid® is linoleic acid, in 
ClinOleic® oleic acid, and SMOFLipid® 
consists more evenly of several triglycerides 
than the other two. In addition to different 
triglyceride compositions between different 
lipid emulsions, the exact triglyceride 
concentrations vary also in the oils they are 
derived from (Fatemi and Hammond, 1977), 
which causes a variation in the final product 
(Fresenius Kabi AB, 2013). Even though the 
composition affects the stability of the lipid 
emulsion and even the immunologic 
responses (Calder et al., 2010), comparative 
studies have shown no marked difference in 
rescue potential of different lipid emulsions 
in LAST (Bonfim et al., 2012; Candela et 
al., 2010; Udelsmann and Melo, 2015), and 
the present treatment guidelines do not 
distinguish any lipid emulsion from others 
(Cave et al., 2010; Neal et al., 2012). 
 The recommended dosage of lipid 
emulsion in lipid rescue for LAST is 1.5 ml 
kg–1 bolus in 1 min followed by 0.25 ml kg–
1 min–1 infusion (Cave et al., 2010; Neal et 
al., 2012). For a 70-kg patient, the bolus 
dose would be approximately 100 ml which 
is approximately the highest volume that 
can be given through a peripheral 18G 
cannula in 1 min. However, in most 
experimental studies the lipid emulsion dose 
has been much higher, varying from 4 to 10 
ml kg–1 (Fettiplace et al., 2015; Fettiplace, 
Akpa, et al., 2014; Hicks et al., 2009; 
Udelsmann and Melo, 2015). Such high 
volumes would likely be impossible to 
administer to clinical patients though 
peripheral i.v. routes in a rapid manner. 
 
Liposomes 
In addition to lipid emulsions, various lipid 
nanoparticles, such as liposomes (100–200 
nm) and lipid nanocapsules (~100 nm), have 
been developed for treatment of severe 
intoxication of lipophilic drugs (Dhanikula, 
Khalid, et al., 2007). Liposomes consist 
usually of phospholipid bilayers that form a 
spherical lamellar particle (Damitz and 
Chauhan, 2015). To enhance the effect of 
liposomes, the pH of the inner aqueous part 
can be modified to cause ionisation of the 
drug within the liposome. After ionisation, 
the drug cannot anymore permeate the lipid 
bilayer. The liposomes can also be charged 
negatively to increase their interaction with 
positively-charged drugs (Damitz and 
Chauhan, 2015). Therefore, the basic 
principle is the same as in the case of lipid 
emulsion: to create liposomes that entrap the 
lipophilic molecules as much as possible in 
order to prevent their action.  
 These liposomes also seem to be 
more effective in entrapping bupivacaine 
compared to lipid emulsions (Litonius, 
Lokajová, et al., 2012). In some cases 
liposomes could be used also as an antidote 
carrier (Damitz and Chauhan, 2015). There 
are, however, possible safety issues before 
the liposomes can be introduced to clinical 
practice as some liposomes may also cause 
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haemodynamic instability (Litonius, 
Lokajová, et al., 2012). The nanosized 
liposomes have shown some promising 
effects in entrapment of amitriptyline 
(Dhanikula, Lamontagne, et al., 2007; 
Howell and Chauhan, 2008) and treatment 
of clomipramine poisonings (Cave et al., 
2013). 
 The treatment of poisonings is not the 
only medical application for liposomes. The 
most important use for these liposomes is to 
act as drug delivery systems. They are used 
in delivery of various drugs, e.g. cytostatics, 
anti-fungals, and antibiotics (Allen and 
Cullis, 2013). In the field of 
anaesthesiology, they have also shown 
promise in prolonging the action of epidural 
anaesthesia if used as a drug carrier (Leng et 
al., 2012). 
 
HAEMODYNAMIC EFFECTS OF THE LIPID 
EMULSION 
The results of the present study (II–V) 
indicate that the clinically recommended 
lipid emulsion dose of 1.5 ml kg–1 followed 
by infusion of 0.25 ml kg–1 min–1 (Cave et 
al., 2010; Neal et al., 2012) may be too 
small to produce any resuscitative effect – at 
least in case of LAST. The lack of effect of 
the recommended dose has been shown also 
earlier (Litonius et al., 2012b; Litonius, 
Tarkkila, et al., 2012) while higher doses 
from 4 ml kg–1 on have shown promising 
results on haemodynamic recovery and 
pharmacokinetic effects (Candela et al., 
2010; de Queiroz Siqueira et al., 2014; 
Fettiplace, Akpa, et al., 2014; Shi et al., 
2013; Udelsmann and Melo, 2015). The 
beneficial effects of the higher lipid 
emulsion doses are likely not due to 
entrapment. Even theoretically, lipid 
emulsions should entrap local anaesthetics 
only marginally (Damitz and Chauhan, 
2015). 
 In Study V, the administration of 4 
ml kg–1 of lipid emulsion, 2.7 times higher 
bolus dose than clinically recommended in 
LAST, increased peripheral vascular 
resistance, which caused a rapid increase in 
arterial blood pressure. Similar findings in 
another recent pig study support the role of 
vasoconstriction as an important mechanism 
of action of lipid rescue (Udelsmann and 
Melo, 2015). Also in rats, the administration 
of lipid emulsion increases the carotid 
resistance in bupivacaine intoxication 
(Fettiplace, Akpa, et al., 2014). Injection of 
massive lipid emulsion dose, 9 ml kg–1, 
alone caused a similar rapid increase of 
arterial blood pressure as in Study V, and 
increased carotid flow (Fettiplace et al., 
2013). In the present study, there were no 
signs of inotropy or improvement of cardiac 
function, i.e. cardiac index or left 
ventricular EF. 
 It is possible that the haemodynamic 
effects of lipid emulsion are mediated by 
α1-adrenoceptors. In human volunteers, the 
α1-adrenergic receptor reactivity increases 
after much lower doses of lipid emulsion 
than used in Study V (Haastrup et al., 1998; 
Stepniakowski et al., 1996), and even a slow 
infusion of lipid emulsion gradually 
increases arterial blood pressure (Kearney et 
al., 2002; Stojiljkovic et al., 2001). In rat 
aorta rings, lipid emulsion similarly 
increases the reactivity to noradrenaline 
after local anaesthetic induced 
vasodilatation (Lee et al., 2013), and can 
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alone reverse the levobupivacaine induced 
vasodilatation (Ok, Park, et al., 2013). 
 α1-adrenoceptors are G-protein-
coupled receptors of which activation 
mediates, for instance, vasoconstriction. In 
the cell, the activation of the receptor 
stimulates phospholipase C activity which 
then through phosphoinositol pathway 
activate protein kinase C (García-Sáinz et 
al., 2000). For instance oleic acid, which is 
one of the main components of Intralipid® 
(see Table 4, page 22), can directly activate 
protein kinase C (Murakami and 
Routtenberg, 1985). The increase in blood 
pressure after oleic acid infusion can be 
prevented with prazosin, an α1-receptor 
blocker (Grekin et al., 1997). In addition to 
protein kinase C -mediated effects, oleic 
acid and palmitic acid, other components of 
Intralipid®, can inhibit the activation of 
endothelial nitric oxide synthase (eNOS) 
independently of protein kinase C activation 
(Davda et al., 1995; Kim et al., 2005). 
Therefore, Intralipid® can directly cause 
vasoconstriction while it also prevents the 
formation of vasodilative nitric oxide. 
 On the other hand, Intralipid® itself 
contains small amounts of arachidonic acid 
and the main component of Intralipid®, 
linoleic acid, is also conversed to 
arachidonic acid (Salem et al., 1999). The 
metabolism of arachidonic acid by 
cyclooxygenase-1 (Brock et al., 1999) and 
cytochrome P450 (Rahman et al., 1997) 
produces several vasoactive metabolites that 
can partly explain the increased peripheral 
resistance. 
 
MITOCHONDRIAL EFFECTS OF LIPID 
EMULSION 
In contrast to previous findings from 
isolated mitochondria (Cela et al., 2010; 
Sztark et al., 1998), bupivacaine did not 
significantly affect mitochondrial 
respiration even though MAP decreased to 
60% of its baseline level, and both cardiac 
index and EF decreased markedly. The 
depression of complex I function by 50% 
occurred, however, at much higher 
bupivacaine concentration of 0.38 mM, i.e. 
110 mg l–1, than in Study V. As the complex 
I -mediated respiration of isolated 
mitochondria was also not altered after a 10-
mg kg–1 bupivacaine dose in rats 
(Partownavid et al., 2012), it is likely that 
the mitochondrial effects of bupivacaine are 
not relevant at bupivacaine concentrations 
during clinical LAST. 
 Even though the mitochondrial 
respiration remained unaltered after giving 
bupivacaine, administration of lipid 
emulsion caused a significant increase in 
oxygen flux after the addition of substrates 
glutamate and succinate, uncoupler FCCP, 
and complex I inhibitor rotenone, while it 
remained unaltered when treatment 
consisted of Ringer’s acetate administration. 
In the aforementioned rat study 
(Partownavid et al., 2012), there was no 
increment in complex I -mediated 
respiration after administration of lipid 
emulsion. They did not, however, include 
any substrates of fatty acid oxidation as we 
did in Study V. The mitochondria were also 
isolated before respirometry, which may 
have affected the results. According to the 
present results it seems possible that lipid 
emulsion slightly increases the cardiac 
Discussion 
 59 
mitochondrial respiration – even though it 
was not accompanied with improved cardiac 
function. 
 
ENTRAPMENT OF DRUGS BY LIPID 
EMULSION 
Theoretically, the predicted entrapment of 
amitriptyline by lipid emulsion is very good 
(Damitz and Chauhan, 2015). This was also 
supported by the present studies as the only 
drug significantly entrapped by lipid 
emulsion after clinically recommended 
rescue doses was amitriptyline (IV). A 
similar increase in blood amitriptyline 
concentration has also been shown 
previously in both pigs and rats but without 
any haemodynamic effects (Litonius et al., 
2012a; Perichon et al., 2013). In Study IV, 
the entrapment was accompanied by a 
favourable resuscitative effect, i.e. lipid 
emulsion reduced amitriptyline 
concentration in the brain. Tissue TCA 
concentrations have not been measured in 
the other studies to confirm the present 
findings, however. 
 All local anaesthetics used seem not 
to be lipophilic enough to be entrapped by 
lipid emulsion (II, III). Even during 
acidosis, which increases the free local 
anaesthetic fraction, lipid emulsion had no 
effect on levobupivacaine concentrations 
(III). Only after a higher lipid emulsion 
dose, bupivacaine was slightly entrapped 
(V). The entrapment of local anaesthetics by 
lipid emulsion has been only marginal also 
in previous studies in which clinically 
recommended lipid emulsion doses has been 
used (Litonius et al., 2012b; Litonius, 
Tarkkila, et al., 2012). Much higher lipid 
emulsion doses can, however, increase the 
blood total local anaesthetic concentration 
(Fettiplace et al., 2015). Such high lipid 
emulsion doses (10 to 15 ml kg–1) can also 
affect the tissue local anaesthetic 
concentrations (Fettiplace et al., 2015; Shi 
et al., 2013), which did not seem to occur 
even after the 4-ml kg–1 dose used in Study 
V. 
 Originally, the lipid sink effect was 
considered the main mechanism of action of 
lipid rescue. At the moment, lipid sink 
seems to be only a minor mechanism of 
action, and may not be important at all in 
case of LAST. 
 
LIPID RESCUE – MULTIPLE SUGGESTED 
RESUSCITATION MECHANISMS OF 
ACTION 
Intralipid®, as well as other lipid emulsions, 
is a combination of several components. 
The amounts of the components can also 
vary between packages (see Table 4, page 
22). The vasoconstrictive effects, as well as 
other possible positive effects, of lipid 
emulsions in treatment of drug intoxication 
are likely mediated by specific fatty acids, 
such as linoleic, oleic or palmitic acid. Even 
though the fatty acids may not be effective 
enough to cause marked vasoconstriction 
themselves, they could be used to sensitise 
α1-adrenoceptors to, for instance, 
noradrenaline (Haastrup et al., 1998; Lee et 
al., 2013; Stepniakowski et al., 1996) after 
local anaesthetic has induced vasodilatation. 
Such sensitisation of α1-adrenoceptors may 
also explain the recovery of some patients to 
whom lipid emulsion had been administered 
in addition to adrenoceptor agonists (Harvey 
et al., 2011; Wong et al., 2010). 
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 Long-chain fatty acids, e.g. oleic, 
linoleic and palmitic acids, seem to increase 
the cardiac calcium concentration (Huang et 
al., 1992), and therefore, improve cardiac 
function. Such cardiac effects could not, 
however, be demonstrated in the present 
study (V). The influence on calcium 
concentration seems, however, to be 
important in treatment of LAST as 
amrinone, a pyridine phosphodiesterase 3 
inhibitor, which inhibits the breakdown of 
cyclic adenosine monophosphate (cAMP) 
and increases intracellular calcium 
concentration, improves the recovery from 
bupivacaine cardiotoxicity (Lindgren et al., 
1992). On the other hand, a calcium 
sensitiser levosimendan does not markedly 
improve the recovery from bupivacaine 
intoxication (Aittomäki et al., 2010). 
Apparently, direct calcium agonists would 
be more effective than lipid emulsion alone. 
It is, however, possible that lipid emulsion 
could enhance the effects of amrinone and 
even levosimendan. 
 As mentioned before, lipid emulsion 
acts as a source of vasoactive prostaglandins 
which may also play a role in lipid 
resuscitation; part of the prostaglandins act 
as vasoconstrictors and part as vasodilators 
(Skeie et al., 1988). Therefore, it could be 
possible to administer only these vasoactive 
prostaglandins instead of lipid emulsion. 
However, lipid emulsion -induced 
vasoconstrictive effects are not necessarily 
positive as lipid emulsion increases also 
pulmonary vascular resistance at least in 
neonates (Prasertsom et al., 1996). In pigs 
and sheep, a similar pulmonary 
vasoconstriction caused by lipid emulsion 
has been linked to vasoactive prostaglandins 
(Bedocs et al., 2014; McKeen et al., 1978). 
Thus, the vasoconstrictive effects on the 
pulmonary circulation may limit the 
applicability of prostaglandins to 
resuscitation use as they may impair the 
oxygenation of blood in the lungs – at least 
in injured lungs (Lekka et al., 2004; Skeie et 
al., 1988). In humans, there are, however, 
no studies on lung function after the higher 
lipid emulsion doses used in lipid rescue. 
 
ADVERSE EFFECTS OF LIPID EMULSION 
As already mentioned in the ‘Adverse 
effects’ paragraph (see page 33), 
administration of lipid emulsion can 
potentially cause several different adverse 
reactions, e.g. hypersensitivity reactions, 
ARDS or pancreatitis. In the only controlled 
human study before Study II, such effects 
were not noted (Litonius, Tarkkila, et al., 
2012). The only adverse effect was 
increased saliva production of one 
volunteer. In Study II, there were no other 
adverse effects than pain in the infusion arm 
during lipid emulsion administration. The 
total number of volunteers in these two 
studies, n=16, cannot, however, exclude a 
possibility of other more serious but less 
frequent complications. 
 In all pig studies (III–V), some of the 
animals developed mild mottling of the skin 
during or after lipid emulsion 
administration. Some researchers have 
suggested that the skin reactions may be 
related to complement activation (see 
‘Limitations’ paragraph below). In none of 
the present studies, skin reactions were 
accompanied with haemodynamic 
instability or increased airway pressures 
suggesting that the skin reactions were not 
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related to any anaphylactoid or anaphylactic 
reactions. In human volunteers (II), redness 
of the skin was not observed during lipid 
emulsion administration. 
 
LAST COMPARED TO OTHER 
COMPLICATIONS OF ANAESTHESIA  
The incidence of serious LAST in Finland 
during the three survey years was very low, 
only 0.7 per 10,000 regional anaesthesias 
which could potentially cause LAST (I). 
Also in France and the US, the incidence of 
LAST has ranged from 0.6 to 1.5 per 10,000 
procedures after excluding spinal 
anaesthesias as in our study (Auroy et al., 
2002; Ecoffey et al., 2014; Sites et al., 
2012). Barrington and colleagues (2013) 
reported that the incidence of serious LAST 
was slightly higher, 3.5 per 10,000 
peripheral nerve blockades, in Australia. 
There is, however, some variation between 
the study settings as in most of the other 
studies only particular procedures were 
included (e.g. axillary brachial plexus block, 
or all peripheral nerve blockades) making 
the direct comparison of incidences 
difficult. 
 Death is a serious complication in 
medical practice. The incidence of death 
related to and primarily due to anaesthesia 
has been declining during the last 60 years 
(Bainbridge et al., 2012; Tikkanen, 1992). 
Within the last two decades, the overall 
incidence of death due to anaesthesia has 
ranged from 5 to 21 per one million 
anaesthesias between different studies 
(Aitkenhead, 2005; Lienhart et al., 2006). 
Schiff and colleagues (2014) showed very 
recently that in otherwise healthy patients 
(American Society of Anesthesiologists 
Physical Status I–II), a death directly 
involving anaesthesia is very uncommon, 
0.7 per one million procedures. The only 
fatality directly involving anaesthesia in that 
study was due to a failed intubation. The 
number of anaesthesia-related deaths is, 
however, higher than that; approximately 
10% of all anaesthesia-related deaths are 
primarily due to anaesthesia or anaesthetics 
(Li et al., 2009). The causes of fatalities due 
to anaesthesia or anaesthetics can be, for 
example, total spinal block by local 
anaesthetics (Auroy et al., 2002; Pitkänen et 
al., 2013), respiratory failure due to 
impossible intubation (Lienhart et al., 
2006), or hypovolemia (Lienhart et al., 
2006).  
 LAST is not the only complication 
related to local anaesthetics and regional 
anaesthesia. Rarely, local anaesthetics can 
cause IgE-mediated, but also other types of, 
allergic reactions, even anaphylaxis (Bhole 
et al., 2012). Similarly, local reactions, such 
as skeletal muscle destruction (Zink and 
Graf, 2004), are rare in clinical setting. 
More common are technical complications, 
i.e. bleeding or nerve damage caused by 
needles or catheters. An analysis of closed 
claims in Finland revealed that the incidence 
of neuraxial haematomas, which can cause, 
for instance, paraplegia, was 0.1 per 
100,000 spinal anaesthesias and 0.4 per 
10,000 epidural anaesthesias (Pitkänen et 
al., 2013). One quite typical complication of 
peripheral nerve blocks is neuropathy, e.g. 
paraesthesia or even neuropathic pain. 
Depending on the block type, the incidence 
of long-lasting neuropathy range from 0 to 
30 per 10,000 blocks (Auroy et al., 2002). 
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LIMITATIONS 
The questionnaire (I) was made 
retrospectively and was based mainly on the 
memory of the department chiefs. It is 
possible that some cases of LAST were not 
reported to them, and therefore, later to us. 
The anaesthesia departments are, however, 
relative small in Finland, and it is unlikely 
that these potentially life-threatening 
complications would not have been reported 
to the department chief. Very similar 
incidence rates of serious LAST from other 
countries support the results of the present 
study (Auroy et al., 2002; Barrington and 
Kluger, 2013; Ecoffey et al., 2014). 
 In Study II, the lipid emulsion bolus 
was given before the lidocaine injection, 
which differs from a clinical situation. The 
CNS effects of 1 mg kg–1 lidocaine are, 
however, short-lived, and passed within 5 
min in that study. To maximise the effect of 
lipid emulsion, the bolus was given in 
advance. 
 All animal studies (III–V) were 
conducted under general anaesthesia with 
isoflurane while all patients are 
unanaesthetised at the time of amitriptyline 
ingestion. Also, most of the patients 
undergoing regional anaesthesia are sedated 
at the most. General anaesthetics have 
shown to protect against, for instance, 
arrhythmias (Warltier et al., 1988), and they 
reduce the systemic toxicity of local 
anaesthetics (Copeland et al., 2008). This 
might explain why serious arrhythmias were 
not noted. The level of anaesthesia was, 
however, similar in both groups in all 
studies, and the isoflurane concentration 
was kept as low as possible at 2.0±0.1% to 
minimise its effects. 
 Some researchers have claimed that 
the pig is unsuitable for lipid rescue 
research (Weinberg and Rubinstein, 2012). 
A reason for the criticism is that pig may 
develop complement activation related 
hypersensitivity reactions (pseudoallergy, 
CARPA) to certain liposomes (Szebeni et 
al., 2007). Such reaction may, however, 
develop also in humans and pig can be used 
as a model of CARPA reactions (Szebeni et 
al., 2007). Even though such complement 
activation cannot be demonstrated in pigs 
after lipid emulsion administration, they 
seem prone to develop haemodynamic 
instability after high doses of lipid emulsion 
(Bedocs et al., 2014). The lipid emulsion 
doses used in the present study were, 
however, smaller, and no particular 
haemodynamic instability was noted. 
Nevertheless, even though pigs are not 
physiologically identical to humans, they 
are considered to be a most suitable animal 
model for both physiological and 
pharmacological research (Swindle et al., 
2012; Yealy, 1993). The pigs resemble 
humans also anatomically, and from a 
practical point of view, all catheters and 
anaesthesia equipment for human use are 
also suitable for pigs weighing 20 to 30 kg. 
On the other hand, widely in lipid rescue 
research used rats have a species-specific 
ability to recover spontaneously from 
ventricular fibrillation (Yealy, 1993). Even 
after cardiac arrest for several minutes the 
heart can be restarted by mechanical 
compression, which does not happen in pigs 
and humans (Yealy, 1993). This ability of 
spontaneous recovery might have helped the 
more favourable results in rats than in pigs. 
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CONCLUSIONS 
The following conclusions can be made based on Studies I–V: 
 
1. The total incidence of local anaesthetic systemic toxicity in Finland is low – only 0.7 
per 10,000 regional anaesthesias, and the incidence of cardiac toxicity is much lower 
(I). Lipid rescue is adopted by less than half of the Finnish anaesthesia departments 
(I). 
 
2. Lipid emulsion does not alleviate CNS toxicity symptoms of lidocaine in human 
volunteers (II). In pigs, lipid emulsion does not improve recovery from 
levobupivacaine intoxication which is exacerbated by acidosis and hypoxaemia as in 
clinical situation (III). 
 
3. Local anaesthetics are not entrapped after intravenously administered lipid emulsion 
in clinically recommended doses and much higher lipid emulsion doses are probably 
needed for any significant entrapment (II, III, V). On the other hand, in clinically 
relevant doses lipid emulsion entraps amitriptyline in plasma to some degree even 
after distribution of amitriptyline (IV). In addition, lipid emulsion can also reduce 
tissue amitriptyline concentration to a slight degree (IV). 
 
4. In pigs, a higher lipid emulsion dose than clinically recommended improves recovery 
from bupivacaine cardiac toxicity through peripheral vasoconstriction, and slightly 
stimulates mitochondrial complex I and II mediated respiration (V). The 
improvement of mitochondrial function does not, however, correlate with cardiac 
function (V). 
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FUTURE IMPLICATIONS 
This study has enlightened the uncertainty 
about the possible mechanisms of action of 
lipid rescue. According to this thesis, the 
effects of lipid emulsion do not emerge until 
a larger dose is used than recommended. 
The dose of 4 ml kg–1, at least in 1 min, is 
too high to be administer to clinical patients 
through peripheral cannulas that do not 
allow such administration rates. Therefore, 
we need more comprehensive dose 
dependence studies to confirm the optimal 
dosage of lipid emulsion. On the other hand, 
we need also more comprehensive studies 
on the safety of the larger doses of lipid 
emulsion. 
 Randomised clinical trials on lipid 
rescue of LAST are difficult, or even 
impossible, to organise as the incidence of 
LAST is so low and it would be impossible 
for the patient to give a written consent to 
the study in an emergency situation. 
Symptoms of LAST also typically ease 
rapidly and treatment of, for instance, 
convulsions with other medication is 
essential, which impedes the evaluation of 
the efficacy of lipid emulsion. However, 
more human volunteer studies could be 
possible to conduct with local anaesthetic 
doses that are known to be safety. On the 
other hand, in cases of ingestion of other 
drugs, such as amitriptyline or other 
lipophilic psychopharmacon, it could be 
possible to study the efficacy of lipid rescue 
in a clinical setting in the emergency 
departments. 
 The best animal model for lipid 
rescue still remains uncertain. On the one 
hand, the physiology and anatomy of 
rodents differ greatly from humans, while 
on the other hand, pigs may be more 
sensitive to especially higher lipid emulsion 
doses than rodents. The effects of high lipid 
emulsion doses in humans are not known. 
We experienced pig a practical animal 
model for lipid rescue studies, but it may 
still be reasonable to find out the best of 
them. 
 The originally proposed mechanism 
of action of lipid rescue, lipid sink, cannot 
account for the main mechanism of action 
and explain the potential positive effects 
seen in clinical case reports. In this thesis, 
two other mechanisms of action, 
vasoconstriction and slightly stimulated 
mitochondrial respiration, were shown. To 
fully understand the efficacy of lipid 
emulsion, we still need to dig more deeply 
into the mechanisms and even to study new 
possibilities, such as prostaglandins. 
 In addition to studies on mechanisms 
of action of lipid rescue, more specific 
liposomes could prove also more effective 
than the present lipid emulsions. Liposomes 
can be modified to maximise, for example, 
the lipid sink effect, but possibly also other 
effects could be build into them.  
 As lipid emulsion does not prove to 
be a miraculous antidote for LAST, we still 
lack a specific treatment for local 
anaesthetic intoxication and it remains a 
potentially fatal complication. Therefore, we 
need to focus also on the training of both 
young and also more experienced 
anaesthesiologists. The most important 
aspects are the usage of small test doses, 
aspiration, usage of ultrasound, and of 
course, the early recognition of the 
symptoms of LAST. The best treatment for 
LAST is to prevent them. 
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 As LAST is, luckily, a rare 
complication of regional anaesthesia, we 
would need an international, e.g. 
Scandinavian or European, registry into 
which all cases could be reported. Such 
registry would provide more information 
about the circumstances leading to LAST, 
which would be useful in the training of 
anaesthesiologists.  
 Education, monitoring, rapid 
intervention are no new means for safe 
performance of regional anaesthesia but 
their role needs to be reemphasised. 
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Name
Phone number
Department
Email
QUESTIONNAIRE REGARDING LOCAL ANAESTHETIC SYSTEMIC TOXICITY
2011–2013
RESPONDER INFORMATION
NUMBER OF LOCAL ANAESTHETIC PROCEDURES PERFORMED BY ANAESTHESIOLOGISTS DURING 2011–2013 (TOTAL)
For surgery and post-operative pain management
Exact number Estimation Number
Spinal anaesthesia
Epidural anaesthesia
CSE (combined spinal and epidural anaesthesia)
Regional block
Intravenous regional anaesthesia
Systemic lidocaine infusion
For obstetrics
Exact number Estimation Number
Spinal anaesthesia
Epidural anaesthesia
CSE (combined spinal and epidural anaesthesia)
Regional block
For management of chronic pain
Exact number Estimation Number
Spinal anaesthesia
Epidural anaesthesia
CSE (combined spinal and epidural anaesthesia)
Regional block
Intravenous regional anaesthesia
Systemic lidocaine infusion
TREATMENT PROTOCOL
Yes No
Our department has a treatment protocol for local anaesthetic systemic toxicity
Yes No
If yes, intravenous lipid emulsion is part of the protocol
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Submit
Yes No
If yes, lipid emulsion is stored in a resuscitation trolley
Intralipid 20% CliOleic 20% Other, what What?
If yes, lipid emulsion product
Recommendation on LipidRescue.org by ASRA by AAGBI Other, what What?
If yes, the dosing is based on
LOCAL ANAESTHETIC SYSTEMIC TOXICITY IN THE DEPARTMENT 2011–2013
Yes No
There has been a case/cases of local anaesthetic toxicity in our department during 2011–2013
If yes, the number of local anaesthetic toxicity
Number of cases
Most serious symptoms were central nervous system symptoms
Most serious symptoms were cardiac symptoms
Local anaesthetic toxicity was fatal
If yes, intravenous lipid emulsion was used as a part of treatment of local anaesthetic toxicity
Number of cases
Most serious symptoms were central nervous system symptoms
Most serious symptoms were cardiac symptoms
Local anaesthetic toxicity was fatal
PROCEED
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